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Abstract 29 
Background: Non-homologous end-joining (NHEJ) is the major DNA double strand 30 
break (DSB) repair mechanism in human cells. The final rejoining step requires DNA 31 
ligase IV (LIG4), together with partner proteins, XRCC4 and XLF. Patients mutated in 32 
genes encoding LIG4, XLF or other NHEJ proteins DNA-PKcs and Artemis are DSB 33 
repair defective and immunodeficient, due to the requirement for NHEJ during V(D)J 34 
recombination. 35 
Objective: We found a patient displaying microcephaly and progressive ataxia but a 36 
normal immune response. We sought to determine pathogenic mutations and to describe a 37 
molecular pathogenesis of the patient. 38 
Methods: We performed NGS exome sequencing. We evaluated DSB repair activities and 39 
V(D)J recombination capacity of the patient cells as well as a standard blood 40 
immunological characterisation. 41 
Results: We identified causal mutations in the XRCC4 gene. The patient cells are 42 
radiosensitive and display the most severe DSB repair defect that we have encountered 43 
using patient derived cell lines. In marked contrast, a V(D)J recombination plasmid assay 44 
revealed that the patient cells did not display the junction abnormalities that are 45 
characteristic of other NHEJ-defective cell lines. The mutant protein can interact 46 
efficiently with LIG4 and functions normally in in vitro assays and when transiently 47 
expressed in vivo. However, the mutation makes the protein unstable and it undergoes 48 
proteasome-mediated degradation. 49 
Conclusion: Our findings reveal a novel separation of impact phenotype: there is a 50 
 4 
pronounced DSB repair defect and marked clinical neurological manifestation but no 51 
clinical immunodeficiency. 52 
53 
 5 
Capsule Summary 54 
A patient with mutations in the XRCC4 gene, encoding a DNA double-strand-break 55 
(DSB) repair factor, displayed severe radiosensitivity and neurological abnormalities but 56 
maintained normal V(D)J recombination function. Our findings suggest a separation of 57 
impact phenotype. 58 
 59 
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repair-deficiency; XRCC4/LIG4; immunodeficiency; microcephaly 62 
 63 
Abbreviations 64 
NHEJ: Non-homologous end-joining 65 
CSR: Class switch recombination 66 
CID/SCID: Combined or severe combined immunodeficiency 67 
DSB: DNA double strand break 68 
hTERT: Human telomerase reverse transcriptase 69 
RRS: Recovery of RNA synthesis 70 
UDS: Unscheduled DNA synthesis  71 
RDS: Recovery of DNA synthesis 72 
NMD: Nonsense mediated mRNA decay 73 
PARP: poly ADP ribose polymerase  74 
NER: Nucleotide excision repair 75 
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 77 
Introduction 78 
DSBs arise from oxidative damage and during processes such as meiosis or V(D)J 79 
recombination. They are also the major lethal lesions generated in cellular DNA by 80 
ionizing radiation. Although DSBs do not arise at high frequency endogenously, they are 81 
a critical lesion causing cell death or carcinogenesis if misrepaired. Additionally, the 82 
development of the immune response involves the introduction of DSBs to generate the 83 
requisite genetic diversity.1 V(D)J recombination represents one such process.2 Class 84 
switch recombination (CSR), which involves the switching of immunoglobulin isotypes, 85 
also involves the introduction and rejoining of DSBs.3 86 
NHEJ is the major DSB repair process in mammalian cells. The process is 87 
initiated by the binding of the Ku heterodimer to double-stranded DNA ends followed by 88 
the recruitment of the DNA-dependent protein kinase catalytic subunit, DNA-PKcs, 89 
generating the DNA-PK holoenzyme and activating DNA-PK activity.4 DNA-PK has a 90 
role in end-tethering and regulates steps of end-processing. The final step of rejoining 91 
involves the recruitment of a ligation complex encompassing DNA ligase IV (LIG4), 92 
XRCC4 and XLF. LIG4 and XRCC4 interacts strongly via a tandem BRCT domain in 93 
LIG4 and a coiled coil region in XRCC4, forming a highly stable complex.5, 6 XRCC4 is 94 
required for LIG4 stabilisation but recent findings have shown an excess of XRCC4 95 
relative to LIG4.7 Mutations that abolish LIG4/XRCC4 interaction prevent all NHEJ 96 
activity. XLF is a weaker binding partner. XRCC4 and XLF are structurally similar; both 97 
have a globular head domain, but the coiled coil region of XLF is shorter than that in 98 
XRCC4.8, 9 Recent studies have reported that dimers of XRCC4 and XLF interact to form 99 
long superhelical filaments in solution, which have been proposed to promote 100 
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end-tethering or end-bridging downstream of the DNA-PK complex.8, 10-12 101 
 Loss of LIG4 or XRCC4 confers embryonic lethality in mice due to extensive 102 
neuronal apoptosis.13, 14 In contrast, XLF null mice are viable and do not show marked 103 
immunodeficiency.15 Mutations in LIG4, DCLRE1C (Artemis), NHEJ1 (XLF) and 104 
PRKDC (DNA-PKcs) in patients have been described.16-20 LIG4 syndrome, which is 105 
caused by hypomorphic mutations in LIG4, is characterised by growth delay, 106 
microcephaly, and combined or severe combined immunodeficiency (CID/SCID). LIG4 107 
syndrome cell lines show radiosensitivity, diminished ability to repair DSBs and impaired 108 
V(D)J recombination. XLF defective patients, some of which have null mutations, 109 
display features similar to, although often more severe than LIG4 syndrome.18 Given the 110 
close interaction and requirement of XRCC4 for LIG4 stability, the expectation was that 111 
XRCC4 deficiency in patients would resemble LIG4 syndrome. 112 
 In contrast to this expectation, an XRCC4-deficient patient, CSL16NG, whose 113 
cellular defects we describe in this paper, displayed unique clinical features similar to 114 
those of Cockayne Syndrome, namely progressive neuronal degeneration including the 115 
onset of ataxia, but no clinical immunodeficiency. Our cellular analysis revealed that the 116 
mutational changes result in substantially reduced levels of XRCC4 protein, a marked 117 
defect in DSB repair but seemingly efficient V(D)J recombination. Based on comparative 118 
studies with LIG4 and XLF deficient cell lines, our results reveal a separation of impact 119 
phenotype where marked deficiency in radiation-induced DSB repair capacity can be 120 
uncoupled from defective V(D)J recombination. Our results give novel insights into the 121 
roles of XRCC4 during DSB repair.  122 
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Methods 123 
Human studies 124 
Patient and control samples were obtained with local ethical approvals [University of 125 
Sussex Research Ethics Committee; Nagasaki University Ethical, Legal and Social 126 
Implications (ELSI) committee; Ethics committee for human genome studies in 127 
Research Institute of Environmental Medicine, Nagoya University]. Written informed 128 
consent was obtained from the patient. 129 
 130 
Exome sequencing and bioinformatics 131 
Details are described in Supplementary Methods. Briefly, genomic DNA prepared 132 
from CSL16NG fibroblasts was enriched using the SureSelect All Exon Kit v5 (Agilent), 133 
followed by sequencing on the Illumina Hiseq 2500 sequencer. The sequence data were 134 
analysed by a standard exome pipeline. According to a recessive inheritance model, we 135 
selected genes that carried at least one novel deleterious homozygous or more than two 136 
heterozygous changes in one gene locus (Table S1). 137 
 138 
Cell cultures 139 
Human primary or hTERT immortalized fibroblasts were derived from the XRCC4 140 
patient (CSL16NG), LIG4 patients (F07/614, 180BR, 411BR, 2303 and 495GOS), XLF 141 
patients (2BN and F07/402), an XP patient (XP15BR) or healthy donors (1BR.3 and 142 
48BR). All primary fibroblasts were cultured in Dulbecco′s Modified Eagle Medium 143 
(DMEM) or Modified Eagle Medium (MEM), supplemented with 10-15 % fetal bovine 144 
serum (FBS) and 1× penicillin-streptomycin (PS). HEK293FT cells (Invitrogen) were 145 
grown in DMEM supplemented with 10 % FBS, 1× PS, 5 mM L-glutamine, 0.1 mM 146 
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Non-Essential Amino Acids (NEAA) and 1 mM sodium pyruvate. Human colon cancer 147 
HCT116 (RCB2979) and HCT116-XRCC4 (-/-) (RCB2981) cells were provided by the 148 
RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan. 149 
 150 
Reagents and Antibodies 151 
Antibodies used were: XRCC4 (C4 and C20, Santa Cruz Biotechnology), LIG4 (D8, 152 
Santa Cruz Biotechnology; Ab80514, Abcam; 12695-1-AP, Proteintech Group), p89 153 
(S-19, Santa Cruz Biotechnology), XPG (8H7, Santa Cruz Biotechnology), CSB (Bio 154 
Matrix Research), V5-tag (MBL), Flag-tag (MBL), Actin (Ab8227, Abcam), 155 
Alpha-tubulin (Invitrogen), XLF (ab33499, Abcam; FL-299, Santa Cruz Biotechnology), 156 
53BP1 (Bethyl) and gamma H2A.X (ser139, Millipore). MG132, E64D, 157 
3-Methyladenine (3-MA), Epoxomicin, and Cycloheximide (CHX) (Sigma-Aldrich). 158 
 159 
Quantitative RT-PCR 160 
Details are as described previously.21 Total RNA was extracted using the RNeasy Plus 161 
Mini Kit (QIAGEN). The High-capacity RNA-to-cDNA kit (Applied Biosystems) was 162 
used for 1st strand synthesis. Quantitative PCR was performed using the Thermal 163 
Cycler Dice Real-Time system (TaKaRa Bio) with a QuantiTect SYBR Green PCR Kit 164 
(QIAGEN). For each sample, the relative mRNA expression levels were normalized 165 
using the HPRT1 gene. Error bars represent the S.D. of means of triplicate experiments. 166 
 167 
Lentivirus experiments 168 
Details are as described previously.22 Recombinant lentivirus particles expressing 169 
XRCC4 and its mutants were produced. Human XRCC4 cDNA was cloned in frame 170 
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with a C-terminal V5-tag in the pLenti6.3-V5-D-TOPO vector to generate 171 
pLenti6.3-XRCC4-V5 plasmid. The truncation mutant (XRCC4-Del), the frameshift 172 
mutant (XRCC4-Fs), and the single amino-acid substitution mutant (XRCC4-W43R) 173 
were generated from pLenti6.3-XRCC4-V5 by site-directed PCR mutagenesis. 174 
Sequences of the mutant plasmids were confirmed by Sanger sequencing (Figure S1). 175 
48 hours after lentivirus infection, 10 μg/ml of blasticidin (Sigma-Aldrich) was added to 176 
the medium for selection of XRCC4 stably expressing cells. 177 
 178 
Ionizing irradiation and H2AX foci assay 179 
Cells were seeded in 3 cm dishes or in 96-well plates (BD Falcon) and 3Gy Ȗ-ray 180 
irradiated using a 137Cs Ȗ-ray source at a dose rate of 0.017 Gy s-1, then further cultured 181 
for indicated time periods. Cells were fixed with 4 % formaldehyde and permeabilized 182 
with 0.2 % TritonX-100, followed by staining with DAPI and ȖHβAX antibody. Image 183 
acquisition and analysis were performed using the Cellomics ArrayScan VTI (Thermo 184 
Scientific). The average number of separate ȖHβAX foci was assessed on at least γ00 185 
cells. 186 
 187 
NHEJ-, V(D)J- and CSR assays 188 
The assays were performed as previously described.23, 24 For NHEJ-assay, 1 g 189 
PDVG94 plasmid, digested with EcoRV and Eco47III (Promega) to create blunt ends 190 
with 6 bp repeats, were transiently transfected into fibroblast cells using Turbofect 191 
(Fermentas). 48 h after transfection, cells were harvested and DNA extracted using 192 
DNeasy blood and tissue kit (QIAGEN). The recombined junctions were PCR amplified 193 
with primers FM30 and DAR523 and the PCR product was gel purified using Qiaquick 194 
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gel extraction kit (QIAGEN), cloned into pGEM-T vectors and sequenced (Macrogen). 195 
The V(D)J-assay was performed as the NHEJ-assay except that in total 1.5g of 196 
PDVG93 circular plasmid, RAG1 and RAG2 plasmids were transiently transfected into 197 
fibroblast cells and the coding junctions were amplified by a nested PCR using the 198 
primers NV05F (5’-CTATAGGGGAATTGTGAGCGGATAACDG-γ’), DG147 and 199 
DG89, FM30.23 Switch recombination junctions were PCR amplified, cloned, 200 
sequenced and analysed as described previously.25, 26 201 
 202 
Protein purification  203 
Detailed protein purification procedures and buffer conditions are as described 204 
previously.21, 27 Briefly, HEK293FT cells were co-transfected with the 205 
pLenti6.3-LIG4-His and pLenti6.3-Flag-XRCC4, or its mutants. Cell lysates were 206 
incubated with anti-Flag M2 beads (Sigma-Aldrich) for 4 hours at 4 °C. After extensive 207 
washing of the beads, the Flag-tagged wild type (WT) or mutant XRCC4 in complex 208 
with LIG4 was eluted with Flag-peptide. The eluted complexes were dialyzed, 209 
concentrated and stored at -80°C. For expression and purification of GST-XLF protein, 210 
E.coli BL21 (DE3) cells were transformed with pGEX6-GST-XLF plasmid. The 211 
GST-XLF protein was induced with IPTG. The cells were harvested, lysed and cleared 212 
lysate was loaded onto a GSTrap HP column (GE Healthcare). After washing, the 213 
GST-XLF protein was eluted by reduced L-glutathione (Wako). The eluted proteins 214 
were dialyzed, concentrated and stored at -80°C. 215 
 216 
In vitro DSB ligation assay 217 
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A 934 bp Cy5-labeled double strand DNA fragment was PCR amplified from 218 
pEGFP-C3 vector using a set of primers (Forward: 219 
5’-Cy5-GTTTCGCCACCTCTGACTTGAGCG-γ’; Reverse: 220 
5’-GAACTTCAGGGTCAGCTTGCCGTAG-γ’). The DNA fragment was digested with 221 
NcoI (TaKaRa). A 545 bp fragment (Cy5 labeled at the 5’ blunt-end and a γ’-overhang 222 
end) and a 255 bp fragment (with 4 bp overhangs at each end) were purified. The 223 
complexes were incubated for 30 min at 37 °C in a 30 l reaction mixture (66 mM 224 
Tris-HCl pH7.5, 5 mM MgCl2, 1 mM DTT, 1 mM ATP) with 50 ng of DNA substrates 225 
(the Cy5-labeled 545 bp fragment: the unlabeled 255 bp fragment = 2: 3). Reaction 226 
mixtures were pre-incubated for 10 min on ice with GST-XLF, and then LIG4-XRCC4 227 
complex was added at 37 °C for 15 min. The reactions were terminated by adding 1.5 μl 228 
of 10 % SDS, followed by purification with QIAquick PCR Purification kit (QIAGEN). 229 
30 l of the eluted DNA was mixed with 10× loading buffer, incubated at 65 °C for 5 230 
min and cooled on ice rapidly. 15 l of the DNA was run on 1 % agarose gel and 231 
analyzed by the Typhoon imager (GE Healthcare). 232 
 233 
Analysis of protein stability 234 
HEK293FT cells were transiently transfected with XRCC4 or its mutant plasmids. Cells 235 
were treated with CHX (100 μg/ml) combined with MG1γβ (β0 μM), E64D (β0 μM), 236 
Epoxomicin (1 μM) or γ-MA (10 mM). Cells were harvested at the indicated time 237 
points. Whole cell lysate was analysed by Western blotting using anti-V5 antibody. 238 
 239 
Immunoprecipitation 240 
Immunoprecipitation of ectopically expressed WT or mutant XRCC4 proteins in 241 
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CSL16NG cells was performed on cell extracts using anti-V5 agarose (MBL). 242 
Immunoprecipitates were washed five times with lysis buffer containing 0.15 or 1 M 243 
NaCl, then eluted using V5-peptide (2 mM, MBL). The eluted proteins were separated 244 
on 5-20 % gradient SDS-PAGE gels, blotted onto PVDF membranes and analyzed by 245 
Western blotting. 246 
 247 
Confocal Fluorescence Microscopy 248 
Cells were washed once with PBS (Wako) and fixed with Fix buffer [300 mM sucrose, 249 
2 % (v/v) formaldehyde, and 0.2 % (v/v) Triton X-100 in PBS]. After a brief washing in 250 
PBS, cells were blocked with 10 % FBS in PBS for 30 min and then incubated for 1 h 251 
with the anti-V5-tag, anti-ȖHβAX, anti-LIG4 or anti-XRCC4 antibodies at appropriate 252 
dilution. The cells were then washed three times with PBST (0.05 % Tween-20) and 253 
incubated with Alexa fluor488-conjugated secondary antibody at a dilution of 1:500 for 254 
1 h. To visualize nuclei, the cells were incubated with DAPI (10 ng/mL) for 15 min. 255 
Cells were then washed and mounted, and examined on a LSM 700 laser scanning 256 
confocal microscope (Carl Zeiss). Images were taken with the 40× oil immersion 257 
objective lens under identical imaging settings. 258 
 259 
Survival analysis 260 
Fibroblasts were irradiated using a 137Cs Ȗ-ray source at a dose rate of 0.09 Gy s-1. 261 
Radiosensitivity was assessed by colony survival analysis. Cells were trypsinised, 262 
irradiated and plated onto feeder cells prepared 24 h earlier and left to form colonies for 263 
three weeks. For XRCC4 complementation experiments, normal (48BR), CSL16NG 264 
and CSL16NG-derived fibroblasts expressing WT XRCC4 were seeded in 96-well 265 
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plates (BD Falcon). After Ȗ-ray irradiation, cells are incubated for a further 24 hours. 266 
Sensitivity to IR was measured by recovery of DNA synthesis (RDS) analysis as 267 
described in supplementary methods (RRS, UDS and RDS assays). 268 
  269 
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Results 270 
Patient CSL16NG has compound heterozygous mutations in XRCC4 271 
Patient CSL16NG, the first daughter of non-consanguineous Caucasian parents, had 272 
significant intrauterine growth failure and microcephaly at birth. She showed slow 273 
growth, delayed motor development and dysmorphic features. Her stature, 274 
developmental delay, deep-set eyes and other features resembled those of Cockayne 275 
syndrome (CS). However, she had no history of photosensitivity and relatively slow 276 
progression of symptoms. She developed progressive ataxia. At 19 years, she was 277 
diagnosed with a low-grade thalamic glioma, which was not removed. She has 278 
hyperopia, diabetes mellitus, hypothyroidism, moderate hearing loss and slurred speech, 279 
although her understanding remains good. Her neurology has been described previously 280 
(Patient 3 in28). She has no significant infectious history and no obvious signs of 281 
abnormal immune response. Detailed routine blood immunological peripheral blood 282 
tests did not reveal any abnormality. Blood cell counts including peripheral blood 283 
lymphocyte sub-type numbers, immunoglobulin IgM, IgG and IgA levels were normal. 284 
Autoantibodies were negative and specific vaccine antigen antibody responses were 285 
present (Table S2). She is currently 23 years old (Her weight is 41.4 kg (<<3rd centile), 286 
head circumference 42.5 cm (<<3rd centile) (Figure 1A). 287 
 As a diagnosis of CS was considered, cellular tests for abnormal responses to 288 
UV light were carried out on a fibroblast culture established from a skin biopsy, but no 289 
abnormality typical of CS cells was observed (Figures S2A-C). Heterozygous 290 
mutations in two CS-related genes (ERCC6/CSB and ERCC5/XPG) were identified but 291 
both alleles were inherited from the asymptomatic father. Both proteins were expressed 292 
at normal levels (Figures S2D and S2E). Whole exome sequencing was carried out and 293 
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of the five potentially pathogenic candidate genes identified (details are described in 294 
Supplemental Method; Tables S1) XRCC4 was the strongest. One mutation (c.C673T, 295 
p.R225*) introduced a premature stop codon; the second mutation (c.G760del, 296 
p.D254fs*68) was a frameshift (Figure S3A, confirmed by Sanger gDNA sequencing), 297 
which predicted the expression of a protein with an aberrant C-terminal 68 amino acids 298 
(aa), resulting in a 322 aa protein (normal full-length protein has 334 aa). 299 
 Allele-specific quantitative RT-PCR (qRT-PCR) using primers that selectively 300 
amplify the wild type (WT) or the mutant XRCC4 cDNAs (Figure S3B and in Table 301 
S3) revealed extremely low expression of the p.R225* allele, consistent with strong 302 
nonsense mediated mRNA decay (NMD) caused by the premature stop codon (Figure 303 
S3C, middle panel; Figure S3D, left panel). The other allele encompassing the 304 
p.D254fs*68 frameshift mutation (designated as XRCC4-Fs hereafter) was expressed at 305 
~30% of the total XRCC4 expression level in normal 48BR cells (50% would be 306 
expected if fully expressed from one allele). The small decrease in the frameshift 307 
transcript level could reflect some NMD, although we note that the newly generated 308 
premature termination codon is located in the last exon, which does not normally trigger 309 
NMD. The mutational change could additionally affect the splicing efficiency or 310 
accuracy, which may also cause NMD (Figure S3D, middle panel; Figure S3C, left 311 
panel). No detectable XRCC4 was observed by immunoblotting of CSL16NG cells 312 
using a mouse anti-XRCC4 antibody with an epitope located close to the N-terminus of 313 
XRCC4 (Figure 1B). We could detect XRCC4 from a control fibroblast diluted ten-fold 314 
arguing that there is less than 10% of the normal level of XRCC4 in the patient cells. 315 
 XRCC4 is reported to co-stabilise LIG4.5, 29, 30 Consistently, LIG4 was 316 
significantly reduced in CSL16NG fibroblasts assessed by immunoblotting (Figure 1B, 317 
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1C). The level of LIG4 appeared to vary depending on conditions and antibody (see 318 
Figure 1B, 2nd and 3rd panel). When compared with the LIG4-null cell line N114P2 319 
(LIG4-/-), a band of LIG4 was clearly visible (Figure 1C) and, from the results of many 320 
experiments, we estimate a residual level of between 5 and 15% of normal. We also 321 
analysed XRCC4 expression by immunofluorescence (IF), which revealed a low signal 322 
in CSL16NG cells detectable in both the cytoplasm and nucleus (Figure 1D). 323 
 324 
CSL16NG cells are radiosensitive and DSB repair defective. 325 
CSL16NG primary fibroblasts showed marked radiosensitivity relative to control cells 326 
(Figure 2A and Figure S4) and reduced recovery of replication after radiation exposure 327 
(Figure 2B). Further, CSL16NG cells showed diminished DSB repair capacity, assessed 328 
by enumerating H2AX foci (Figure 2C, compare red and white bars). In order to 329 
confirm that these defects are attributable to the mutation in XRCC4, we analysed the 330 
ability of WT XRCC4 to correct the defect in CSL16NG cells. When lentivirus 331 
expressing XRCC4-Wt cDNA was used to infect CS16LNG cells, both the ability to 332 
synthesise DNA after irradiation (Figure 2B) and the repair of DSBs (Figure 2C, green 333 
bars) were restored to normal levels. 334 
 335 
CSL16NG cells are defective in a plasmid DSB rejoining assay 336 
We next examined the fidelity of repair in CSL16NG cells using an NHEJ end-joining 337 
assay that involved transfection of CSL16NG cells and control cells with linearised 338 
blunt end plasmids encompassing a 6 bp identical repeat at both DNA ends.23 Whereas 339 
the junctions from control cells were preferentially repaired by direct end-joining, this 340 
type of repair was nearly absent in CSL16NG cells (2 % vs 72 % in control, Table 1). 341 
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Instead, the repair of CSL16NG cells was mediated by the usage of 6 bp 342 
microhomology (78 % vs 8 % in controls) at the junctions, consistent with the loss of 343 
efficient NHEJ in CSL16NG cells. A similar skewed repair pattern has previously been 344 
observed in XLF-deficient cells.24 These findings demonstrate a marked impact of the 345 
mutation on the fidelity of DSB repair. 346 
 347 
CSL16NG cells carry out V(D)J recombination with enhanced fidelity compared to 348 
control cells 349 
Defects in NHEJ are usually associated with immunodeficiency. Surprisingly, 350 
CSL16NG has no history of chronic infections, and clinical analysis verified a normal 351 
immune response (see above). To assess the capacity of CSL16NG cells to carry out 352 
V(D)J recombination, we co-transfected CSL16NG cells with RAG1/2 expressing 353 
plasmids together with a V(D)J substrate and assessed the fidelity of recombination.23 354 
Strikingly, in contrast to the NHEJ assay, most coding junctions were accurately 355 
rejoined with little use of microhomology or deletion formation (Table 2). This novel 356 
V(D)J recombination phenotype contrasts with the pattern obtained with cell lines 357 
derived from most LIG4 syndrome and XLF-deficient patients, where coding junctions 358 
are characterized by increased deletions and microhomology usage.16, 18, 23, 31 359 
 360 
CSL16NG cells show altered repair pattern during class switch recombination 361 
To assess class switch recombination (CSR), we examined peripheral blood 362 
mononuclear cells (PBMC) from CSL16NG. The patient was aged 22 when tested, thus 363 
we compared her CSR junctions to our previously published 154 S-S junctions from 364 
healthy adults (Table 3, Figure S5). Amplification of S-S junctions from in vivo 365 
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switched B lymphocytes from the patient revealed a reduced frequency of junctions 366 
repaired by direct end-joining, albeit not to a significant degree (5% vs. 18% in controls, 367 
2, p=0.15), and a markedly increased frequency of repair by unusually long 368 
microhomologies (≥10 bp; 36% vs. 3% in controls). The altered pattern was similar to, 369 
but less prominent than that previously observed in XLF and LIG4 deficient patients.24, 370 
32
 Thus, although the patient has a normal level of serum IgA, the altered pattern of the 371 
CSR junctions still clearly suggests a defect in the recombination process, which relies 372 
on the classical NHEJ machinery. 373 
 374 
Effect of XRCC4-Fs mutation on XRCC4 function 375 
We next examined the impact of XRCC4-Fs on XRCC4 function and protein expression. 376 
We also examined two other forms of XRCC4 protein (Figure S6A): XRCC4-Del has a 377 
stop codon at the position of the frameshift mutation in CSL16NG, and thus lacks the 378 
C-terminal aberrant polypeptide. XRCC4-W43R, contains an amino acid substitution 379 
p.W43R previously identified in a primordial dwarfism (PD) patient.33 Although Trp43 380 
is conserved, there is no current evidence for causality. Following lentivirus infection as 381 
described above, we found that all forms of the protein were expressed (Figure S6B). 382 
Strikingly, normal DSB-repair activity was restored, not only by expression of WT 383 
XRCC4, but also by XRCC4-Fs. Further, XRCC4-Del also complemented the 384 
CSL16NG DSB repair defect whereas XRCC4-W43R showed little complementation 385 
(Figure 2C, purple, blue and orange bars). Lentiviral expression results in XRCC4 386 
overexpression. To examine DSB repair under physiological expression levels, we also 387 
used hTERT-immortalised CSL16NG cells in a plasmid based complementation assay 388 
(Figure S7) and measured DSBs as 53BP1 foci in cells containing the plasmid. Full 389 
 20 
complementation was found using WT XRCC4 protein and substantial, although not 390 
full, correction by XRCC4-Fs (Figure S7B). Untransfected cells in the same population 391 
showed the expected DSB repair defect. 392 
 These findings suggest that the mutant protein can partially function in DSB 393 
repair. This function likely contributes to the residual DSB repair capacity observed in 394 
CSL16NG cells. We also conclude that the W43R mutation impairs XRCC4 function. 395 
 396 
Biochemical characterisation of the mutant XRCC4 proteins 397 
To further examine the functional capacity of XRCC4-Fs, we purified recombinant 398 
XRCC4-LIG4 complexes and examined their activity in vitro. Flag-tagged XRCC4-Wt, 399 
XRCC4-Fs, and XRCC4-Del proteins were co-expressed with WT His-tagged LIG4 in 400 
HEK293FT cells and co-purified by affinity chromatography (Figure 3A; GST-XLF 401 
was purified from E.coli in Figure 3B). XRCC4-Fs and XRCC4-Del formed complexes 402 
with LIG4, demonstrating that the XRCC4 C-terminus is dispensable for complex 403 
formation. 404 
 In vitro ligation assays were performed using a fluorescent-labeled double 405 
strand DNA with a 3' overhang on one side and an additional smaller double strand 406 
DNA substrate with the same 3' cohesive overhang on both sides (Figure 3C). The 407 
ability of the XRCC4-Fs and XRCC4-Del mutants to support LIG4-mediated ligation 408 
was indistinguishable from that of the XRCC4-Wt. Further, the activity was efficiently 409 
stimulated by XLF. We conclude that the effect of these alterations on the XRCC4/LIG4 410 
enzyme activity is relatively minor. This finding explains the substantial 411 
complementation when the mutant proteins are exogenously expressed. 412 
 413 
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XRCC4-Fs is degraded by the proteasome. 414 
Given the low levels of XRCC4-Fs observed in CSL16NG cells and its presence in the 415 
cytoplasm, we examined whether it is subject to proteolytic degradation. To assess this, 416 
we first transiently expressed WT and mutant XRCC4 in HEK293FT cells in the 417 
presence or absence of the protein synthesis inhibitor, cycloheximide (CHX). In the 418 
presence of CHX, XRCC4-Wt protein was stable up to 12 h, whereas XRCC4-Fs was 419 
significantly degraded (Figure 4A). Remarkably, the XRCC4-Del protein was as stable 420 
as XRCC4-W43R. Degradation of XRCC4-Fs was inhibited by addition of the 421 
proteasome inhibitors, MG-132 and epoxomicin (Figure 4B) but unaffected by the 422 
cysteine protease inhibitor E64D, which inhibits calpain and lysosomal proteases, or 423 
3-Methyladenine (3-MA), an autophagy inhibitor (Figure 4B). Consistent with these 424 
observations, the level of endogenous XRCC4 in CSL16NG cells was significantly 425 
enhanced by incubation in MG132 (Figure S8). These findings strongly suggest that 426 
XRCC4-Fs is subjected to proteasome mediated degradation, which provides an 427 
explanation for the very low (indeed undetectable) level of the mutant XRCC4 protein 428 
and the low level of LIG4 in the patient cells. In view of these findings, we predicted 429 
that the enhanced expression of exogenous WT or mutant XRCC4 in CSL16NG cells 430 
would lead to increased LIG4 levels. Indeed, overexpression of WT and XRCC4 mutant 431 
proteins in CSL16NG resulted in recovery of LIG4 protein levels (Figure 4C, compare 432 
lanes 3-6 with lane 2), which is consistent with the ability of XRCC4-Fs to complement 433 
the CSL16NG repair defect. 434 
 Taking the complementation analyses and the biochemical data together, we 435 
conclude that the XRCC4-Fs mutant protein can efficiently complex with LIG4 and 436 
promote DSB rejoining and that a major impact of the change is greatly reduced 437 
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XRCC4-Fs stability due to proteasomal degradation. 438 
 439 
The mutations in CSL16NG confer a separation of impact phenotype. 440 
Despite the DSB repair defect observed in CSL16NG cells and marked developmental 441 
features, the patient had a normal immune response and the patient cells showed 442 
enhanced accuracy in an in vitro assay for V(D)J recombination, in marked contrast to 443 
other NHEJ-deficient patients. A trivial explanation might be that there is sufficient 444 
residual DSB repair activity to support V(D)J recombination but not the efficient repair 445 
of radiation induced DSBs. To gain further insight, we carried out a comparative 446 
analysis of the efficiency of DSB repair of CSL16NG cells and a range of 447 
patient-derived fibroblasts with deficiencies in other NHEJ proteins (XLF or LIG4) 448 
(Figure 5A). Since LIG4 is essential, LIG4 syndrome patients have hypomorphic 449 
mutations and hence a range of clinical severities, which generally correlate with the 450 
magnitude of the repair defect.34 Importantly, most of the LIG4 Syndrome cells 451 
examined (and in total 7/8 lines previously examined by us) repaired most DSBs 452 
induced by 3 Gy IR by 72 h (Figure 5A and data not shown). (495GOS had more 453 
marked sensitivity. This line, however, had normal LIG4 protein expression, raising the 454 
possibility that the mutational change could exert a dominant negative phenotype). 455 
Except for patient 180BR,35, 36 all showed some degree of immunodeficiency. Of 456 
relevance here, the in vitro ligation activities of 411BR and cell line 2303 have been 457 
previously estimated to be < 1%, yet both lines rejoin the DSBs induced by 3 Gy within 458 
72h.34, 37 411BR has previously been shown to express normal levels of mutant LIG434, 459 
37
 but, significantly, 2303 expressed lower levels of LIG4 compared to CSL16NG 460 
(Figures 5B and 5C). Collectively, this analysis of LIG4 syndrome cell lines strongly 461 
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suggests that only a low level of residual LIG4 activity (1% or less) suffices to repair all 462 
DSBs induced by 3 Gy IR, albeit with slow kinetics, a conclusion consistent with 463 
previous findings.38 In marked contrast, CSL16NG fibroblasts, despite harbouring 464 
5-15 % residual LIG4 levels had a severe DSB repair defect. The magnitude of the DSB 465 
repair defect was similar to, although more severe than, that shown by XLF-defective 466 
cells. The repair defect was evident following exposure to a low dose of radiation (0.5 467 
Gy) and, after 3 Gy IR, 25 % of the DSBs remained unrepaired even 8 days post 468 
exposure (Figures S9A and S9B). Indeed, this represents possibly the most severely 469 
DSB repair defective human cell line that we have encountered. In rodent cells, defects 470 
in NHEJ proteins, including XLF can lead to DSB repair by alternative NHEJ 471 
(Alt-NHEJ).39 However, the residual DSB repair in CSL16NG cells is not inhibited by a 472 
PARP inhibitor, KU58958 (Figure S9C) and displays an additive repair defect 473 
following siRNA depletion of LIG4 (Figure S9D) or the addition of a DNA-PK 474 
inhibitor NU7441 (Figures S9C), suggesting that it does not represent Alt-NHEJ but 475 
residual canonical NHEJ activity. This is consistent with current evidence that 476 
Alt-NHEJ does not function in human cells unless Ku is absent.40, 41 We note also that 477 
CSL16NG cells expressed close to normal levels of XLF, as did the LIG4 syndrome 478 
cells examined (Figure 5B). 479 
 These findings show that CSL16NG has a very severe defect in repair of DSB 480 
and importantly, they suggest that the normal immune response of the patient cannot be 481 
attributed to a mild defect in DSB repair, providing evidence for a separation of 482 
function phenotype.  483 
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Discussion. 484 
We describe a patient with mutational changes in the NHEJ protein, XRCC4. The 485 
patient described here has unexpected clinical features for an NHEJ deficiency. Our 486 
detailed cellular analysis provides evidence for a separation of impact phenotype, 487 
namely severely defective DSB repair but normal immune responses, and reveals a 488 
clinical and cellular manifestation for mutations in XRCC4 that is unexpected and 489 
distinct from those conferred by diminished LIG4 enzyme activity. 490 
 In patient CSL16NG, the major expressed allele encodes a protein with 68 491 
aberrant C-terminal amino acids p.(D254fs*68). The mutant protein can interact with 492 
LIG4 and is largely functional for DSB repair in vitro and in vivo. The major impact of 493 
the mutational change is to promote proteasome mediated degradation of the mutant 494 
protein, so that CSL16NG cells have very low XRCC4 protein levels. 495 
 There are two remarkable findings from our results, with important 496 
implications. First, the defect in DSB repair is significantly greater than that of cells 497 
with lower levels of LIG4, and secondly, despite this defect, V(D)J recombination is 498 
proficient and the patient does not display any gross clinical or laboratory 499 
immunodeficiency to date. We will consider these findings in turn. 500 
DSB repair defect. Despite low XRCC4 levels, there is ~5-15 % residual LIG4 501 
localised in the nucleus. This residual activity, by comparison with LIG4 syndrome cells, 502 
is estimated to be sufficient to affect slow DSB rejoining after 3 Gy IR, yet CSL16NG 503 
cells have a dramatic DSB repair defect. These findings, therefore, strongly suggest that 504 
there must be a role for XRCC4 in DSB rejoining that is distinct from its accepted 505 
function in stabilising LIG4.  506 
Recent studies have shown that XLF forms filaments with XRCC4 and 507 
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current models propose that these function in DNA end-stabilisation during DSB 508 
repair.8, 10-12 This structural role for XRCC4 in forming filaments necessitates multiple 509 
XRCC4 molecules at each DNA end and is unlikely to be fulfilled by a low level of 510 
residual XRCC4 protein. The similar DSB repair defect between XLF-deficient and 511 
CSL16NG cells supports an overlapping role in DSB repair. Thus, we propose that the 512 
marked DSB repair defect in CSL16NG cells is a consequence of insufficient XRCC4 513 
to form filaments with XLF. In contrast, low residual LIG4, of which only 1-2 514 
molecules are likely to be required per DSB, is sufficient to allow complete DSB repair 515 
albeit with slow kinetics (Figure S9B). If this hypothesis is correct, our data provide the 516 
first evidence suggesting that XRCC4’s role in XLF filament formation can be 517 
uncoupled from its more direct role in ligation. 518 
DSB repair defect and normal immune response. Despite the marked DSB repair 519 
defect in CSL16NG cells and an altered repair pattern during CSR, the patient did not 520 
display any immunodeficiency, and in a cell based assay, V(D)J recombination took 521 
place with enhanced rather than reduced accuracy. Most LIG4 syndrome cells, including 522 
line 2303, displayed combined immunodeficiency or severe combined 523 
immunodeficiency, yet our comparative analysis of DSB repair showed that most LIG4 524 
Syndrome cells had more efficient DSB repair than CSL16NG.16 Thus the normal 525 
immune response of CSL16NG cannot be attributed solely to a mild DSB repair defect, 526 
suggesting a separation of impact phenotype. 527 
This raises the intriguing possibility that XRCC4’s role in complex with XLF 528 
in end-stabilisation may be dispensable for V(D)J recombination. XLF-deficient 529 
patients, however, do display immunodeficiency demonstrating a role for XLF in V(D)J 530 
recombination in humans.18 There appear to be distinctions between the requirement for 531 
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synapsis/end-stabilisation during V(D)J recombination versus the repair of genotoxic 532 
DSBs. Indeed, XLF is dispensable for V(D)J recombination in mice where ATM, 533 
DNA-PK and 53BP1 have been proposed to have redundant roles, yet XLF deficient 534 
patients frequently display pronounced immunodeficiency.42, 43 We note that the 535 
phenotype of CSL16NG cells overlaps with that of XLF-deficient mice (ie a marked 536 
DSB repair defect but proficient V(D)J recombination).15 Additionally in mice, RAG2 537 
has been proposed to have a role in influencing rejoining during V(D)J recombination.44 538 
We note also that a recent paper identified PAXX as a new XRCC4 super-family 539 
member that functions with XRCC4 and XLF in NHEJ.45 It is possible that there could 540 
be redundancy between PAXX and XRCC4 during V(D)J recombination but not during 541 
the repair of genotoxic DSBs. Further work is required to gain insight into the 542 
mechanism underlying these intriguing findings. 543 
An additional novel phenotype of CSL16NG cells is that all the junctions 544 
formed in the V(D)J recombination assay involved high fidelity joining of the coding 545 
ends. This phenotype contrasts strongly with the lack of direct rejoining of DNA ends in 546 
the NHEJ plasmid assay and the CSR junction analysis, and further supports a 547 
separation of function phenotype. The basis for the difference from control cells in the 548 
V(D)J recombination assay, where small deletions/insertions can arise is unclear. 549 
However the accurate rejoining contrasts to other NHEJ deficient lines, which are 550 
characterised by large deletions and microhomology usage. Although the lack of 551 
junctional diversity seen in this fibroblast based assay might predict a diminished 552 
repertoire of T- and B- cells, it is possible that the assay does not fully reflect the in vivo 553 
process due to differences between fibroblasts and lymphocytes (e.g. T-cells express 554 
tdT). 555 
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Using CSL16NG fibroblasts and the assays established here, we also 556 
examined the impact of W43R, a previously described XRCC4 mutational change 557 
observed in a patient with primordial dwarfism.33 We provide evidence that W43R is a 558 
pathological mutational change, supporting the notion that homozygous expression of 559 
XRCC4-W43R underlies the primordial dwarfism observed in the patient. 560 
Several recent studies have also described patients with mutations in XRCC4.46-49 561 
Strikingly, all patients displayed microcephaly and growth delay but no overt 562 
immunodeficiency (although detailed examination of V(D)J recombination ability was 563 
not investigated in these patients). This strengthens our proposal that XRCC4 deficiency 564 
confers a separation of impact phenotype (impacting upon the repair of genotoxic DSBs 565 
but not the repair of DSBs induced during V(D)J recombination), demonstrating that 566 
this is not a finding specific to our patient. The severe DSB repair defect in CSL16NG 567 
cells also provides a potential explanation for the marked neurological phenotype 568 
observed in the patient. An unusual feature for NHEJ deficiency was the development 569 
of progressive ataxia in the patient and it is tempting to speculate that this is a 570 
consequence of persisting unrepaired DSBs. Intriguingly, a progressive neurological 571 
phenotype involving unsteady gait was recently observed in two XRCC4-deficient 572 
siblings, who similarly had no detectable residual XRCC4 protein.49 This supports the 573 
notion that progressive ataxia could be a consequence of marked XRCC4 deficiency. 574 
The prediction of our working model is that mutations in XRCC4 that result in 575 
low expression of a protein capable of interacting with LIG4 will confer marked 576 
neurological deficits without associated immune deficiency. Given the striking 577 
resemblance of patient CSL16NG, when a young child, to CS patients, XRCC4 should 578 
be considered a candidate for potential causal mutations in further patients with similar 579 
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features, including further CS-like patients with normal transcription-coupled nucleotide 580 
excision repair. 581 
In summary, we describe a patient with mutations in XRCC4. The patient had 582 
marked neurological abnormalities with progressive ataxia. Our biochemical and 583 
cellular analysis provides evidence that the mutational changes in this patient confer a 584 
separation of impact phenotype with a severe defect in DSB repair but no marked defect 585 
in V(D)J recombination. Recent papers have described additional XRCC4-deficient 586 
patients with a normal immune response.33, 46-49 As a working model, we propose that 587 
this could arise from a separation of XRCC4 function in stabilising LIG4 versus its role 588 
in forming filaments with XLF. We propose that XRCC4 is required for all DSB 589 
rejoining since LIG4 is unstable in the absence of XRCC4. However, only a low-level 590 
of protein suffices to provide sufficient LIG4 to effect slow rejoining. In contrast, 591 
XRCC4’s role in filament formation with XLF is essential for efficient rejoining of 592 
genotoxic DSBs but appears to be dispensable during V(D)J recombination in human 593 
cells, possibly due to redundancy with other proteins that can promote synapsis. 594 
 595 
  596 
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Figure legends 800 
Figure 1. Identification of mutations in the XRCC4 gene in CSL16NG 801 
(A) Clinical pictures of CSL16NG at age 1.5, 16 and 23 (with informed written consent 802 
from the patient’s mother). (B) Immunoblotting of XRCC4 and LIG4 proteins in 803 
CSL16NG and HCT116-XRCC4 (-/-) cells as well as normal 48BR, 1BR.3 and 804 
HCT116 cells with alpha-tubulin as a loading control. The black solid arrows indicate 805 
the position of each protein. The dilutions indicate that the amount of XRCC4 in 806 
the patient cells is < 2% (detection limit) of normal cells. (C) Immunoblots 807 
showing the expression of LIG4 proteins in normal (48BR), patient (CSL16NG) and 808 
N114P2 (LIG4 -/-) fibroblasts. (D) Immunofluorescent staining of endogenous XRCC4 809 
protein in normal 48BR, CSL16NG cells. Cells were fixed and immunostained with 810 
mouse anti-XRCC4 antibody (C4, Green). DAPI, DAPI staining (Blue); Merge, merged 811 
picture; Scale bar, 20 µm. 812 
 813 
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Figure 2. CSL16NG defects in DNA double strand break repair 814 
(A) The colony-forming ability of primary CSL16NG cells was compared with that of a 815 
normal control (1BR.3) and that of a LIG4-defective F07/614 cells after treatment with 816 
different doses of Ȗ-ray. The range of sensitivity displayed by another healthy individual 817 
and 20 other individuals deemed to have a normal (or close to normal) response is 818 
shown in Figure S4. In (A), all primary cell lines used were between 5 and 9 passages 819 
following establishment from a skin biopsy. Error bars represent S.D. obtained from 820 
triplicate experiments. (B) CSL16NG cell sensitivity to Ȗ-ray was rescued by 821 
overexpression of the WT XRCC4 protein. Cell proliferation β4 hrs after Ȗ-irradiation 822 
was determined by EdU incorporation and compared with that in unirradiated cells. (C) 823 
Complementation of the DSB repair defect in CSL16NG cells. CSL16NG cells stably 824 
expressing the V5-tagged WT XRCC4 or the indicated mutant XRCC4 proteins were 825 
irradiated with 3 Gy IR. DSB repair kinetics was measured as described above. In (B,C), 826 
primary cell lines used were between 16 and 20 passages following establishment from 827 
a skin biopsy. Error bars represent S.D. obtained from triplicate experiments. 828 
 829 
Figure 3. The XRCC4-Fs-DNA ligase IV complex has normal ligase activity 830 
(A) His-tagged LIG4 and the FLAG-tagged WT and the mutant XRCC4 proteins were 831 
expressed in HEK293FT cells. Total cell lysates were prepared and the XRCC4-DNA 832 
ligase IV complexes were purified on anti-FLAG M2 beads as described in Materials 833 
and Methods. Purified proteins were run on a SDS-PAGE and either stained with 834 
Coomassie brilliant blue (left panel) or immunoblotted with antibodies against LIG4 or 835 
XRCC4 as indicated (right panel). (B) GST-tagged XLF was purified from E. coli BL21 836 
according to the methods described previously.27 (C) The purified XRCC4-DNA ligase 837 
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IV complexes and XLF were incubated with the indicated Cy5-labeled and non-labeled 838 
dsDNA substrates. Ligated products diagrammed at right of figure were identified on 839 
1 % agarose gel electrophoresis by their decreased mobility. 840 
 841 
Figure 4. XRCC4-Fs mutant protein is unstable in cells 842 
(A) Immunoblots of the WT and mutant XRCC4 proteins with CHX (100 μg/ml). (B) 843 
Effects of various chemical compounds on degradation of the XRCC4-Fs protein. 844 
HEK293FT cells were transiently transfected with the XRCC4-Fs cDNA and treated 845 
with cycloheximide together with proteasome inhibitors, MG1γβ (β0 μM) or 846 
epoxomicin (1 μM), protease inhibitor E64D (β0 μM), or autophagy inhibitor 3-MA (10 847 
mM) for the indicated period. DMSO was used as a vehicle control. (C) Overexpression 848 
the WT and the mutant XRCC4 proteins restored LIG4 expression levels. V5-tagged 849 
XRCC4-Wt or mutant proteins were ectopically expressed in CSL16NG cells and the 850 
levels of LIG4 were analysed by immunoblotting with two different antibodies. 851 
 852 
Figure 5. CSL16NG cells show an exceptionally marked DSB repair defect. 853 
(A) Double strand break (DSB) repair kinetics following Ȗ-irradiation were determined 854 
in normal and various DSB-repair deficient patient cell lines. Residual DSBs were 855 
measured by enumeration of the average number of ȖHβAX foci at each indicated time 856 
point. (B) Immunoblots showing the expression of XRCC4, LIG4 and XLF proteins in 857 
cells from normal individuals (1BR.3), patient (CSL16NG) as well as previously 858 
reported XLF-patient (2BN) and LIG4-patients (F07/614 and 2303). (C) Diminished 859 
expression of the LIG4 in CSL16NG cells were confirmed by immunofluorescent 860 
staining. DAPI, DAPI (Blue). All primary fibroblasts used were between 5 and 9 861 
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passages following establishment from a skin biopsy. Error bars represent S.D. obtained 862 
from triplicate experiments.  863 
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Table 1. Increased microhomology-dependent repair in CSL16NG ells in 864 
plasmid-based NHEJ assaya  865 
Cell line 
Direct 
end-joining 6bp MH Deletion+MH 
Deletion 
only 
Total No. of 
junctions 
CSL16NG 
1 
(2%)***↓ 
47 
(78%)***↑ 
3 
(5%) 
9 
(15%) 
60 
XLF-/-b 
3 
(4%)***↓ 
55 
(81%)***↑ 
10 
(15%) 
0 
(0%)**↓ 
68 
411BR 
LIG4dc 
4 
(22%)***↓ 
12 
(67%)***↑ 
0 
(0%) 
2 
(11%) 
18 
Controlsd  
105 
(72%) 
11 
(8%) 
14 
(10%) 
16 
(11%) 
146 
a. Statistical calculations performed by 2 test. Significant changes are indicated in bold. 866 
*p<0.05, **p<0.01, ***p<0.001 867 
b. Previously published results from XLF-deficient cell line.24 868 
c. 411BR, described in.16, 50 869 
d. Newly generated results merged with previously published results from control cell 870 
line.24, 51 871 
  872 
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Table 2. Increased fidelity of end joining at coding junctions in CSL16NG in 873 
plasmid-based VDJ-assaya 874 
Cell line 
Accurate 
end-joining 
4bp MH Deletion+MH 
Deletion 
only 
Total No. of 
junctions 
CSL16NG 
18 
(90%)***↑ 
0 
(0%)*↓ 
2 
(10%)**↓ 
0 
(0%)*↓ 
20 
XLF-/- 
5 
(12%) 
4 
(10%) 
32 
(78%)***↑ 
0 
(0%)***↓ 
41 
Controls 
13 
(10%) 
25 
(20%) 
57 
(46%) 
30 
(24%) 
125 
a. Statistical calculations performed by 2 test. Significant changes are indicated in bold. 875 
*p<0.05, **p<0.01, ***p<0.001  876 
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Table 3. Characterization of S-S junctionsa 877 
a. Statistical analysis was performed using 2 test and significant differences are 878 
indicated in bold. * p<0.05, ** p<0.01, *** p<0.001. 879 
b. Previously published junctions from LIG4-deficient patients and controls.32 880 
n= Indicates number of individuals in each group. 881 
  882 
Patients Perfectly matched short homology 
Total No. of 
S fragments 
 0 bp 1-3 bp 4-6 bp 7-9 bp ≥ 10 bp  
 
Direct 
end-joinin
g 
Small 
insertion
s 
     
CSL16NG 
(n=1) 
1 
(5%) 
2 
(9%) 
4 
(18%) 
2 
(9%) 
5 
(23%)*↑ 
8 
(36%)***↑ 
22 
LIG4db 
(n=2) 
0 
(0%)*↓ 
1 
(3%)**↓ 
7 
(23%) 
4 
(13%) 
4 
(13%) 
14 
(47%)***↑ 
30 
Controlsb 
(n=17) 
28 
(18%) 
39 
(25%) 
56 
(36%) 
15 
(10%) 
11 
(7%) 
5 
(3%) 
154 
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Supplemental Materials 883 
 884 
Supplemental methods 885 
 886 
RRS, UDS and RDS assays 887 
Detailed experimental procedures have been described previously.22, 52, 53 Briefly, 888 
normal 48BR, CSL16NG and XPA patient-derived primary fibroblasts (XP15BR) were 889 
seeded in 96-well plates (BD Falcon). For RRS assay, cells were UV-irradiated (254 nm 890 
UVC, 12 J/cm2) and incubated for 12 hours for RNA synthesis recovery, followed by 891 
ethynyluridine (EU) incorporation. For the UDS and RDS assays, UV- or -ray 892 
irradiated cells were immediately incubated with 5’-ethynyl-β’-deoxyuridine (EdU) for 893 
measuring repair synthesis. After incorporation of EdU or EU, cells were fixed, 894 
followed by Alexa Fluor 488-azide coupling and DAPI staining. Image acquisition and 895 
data processing were automated using the Cellomics ArrayScan VTI (Thermo 896 
Scientific). 897 
 898 
Identification of the pathogenic mutations by exome sequencing 899 
  We performed exome sequencing of the patient, CSL16NG, using the Agilent 900 
SureSelect Exome Target Enrichment System (version.5 50Mbp target), followed by 901 
paired-end sequencing (101 bp/read) on the Illumina Hiseq 2500 sequencer. We 902 
obtained ~193 million reads (~ 19 Giga base pairs). Of the QC-passed initial sequencing 903 
reads, 18.4 Gbp are uniquely mapped to the human reference sequence (b37). Of the 904 
mapped sequences, 12.9 Gbp (66.33%) are further mapped to the target exon regions 905 
with a mean coverage of 89.05x. 98.8% of the target bases were read more than 2x 906 
coverage. We identified a total of 740,166 single nucleotide variants (SNVs) and 88,210 907 
insertions and deletions (indels). To identify potential pathogenetic changes, we firstly 908 
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determined 'functionally significant variants', which are coding non-synonymous SNVs, 909 
stopgains and stoplosses, splice-site variants, and coding indels. We identified 11,505 910 
functionally significant variants. The identified variants were then filtered out to extract 911 
'novel functionally significant variants'. We compared the identified variants with 912 
dbSNP137, 1000 Genomes Project, and 88 in-house exome sequencing data. Variants 913 
found in these databases were excluded. As a consequence of these filtering process, 914 
totally 140 novel functionally significant variants were determined. Based on a 915 
recessive inheritance model, we found 5 pathogenic candidate genes in the patient 916 
(Table S1). 917 
  918 
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Table S1. Novel homozygous and compound heterozygous variants in the 919 
candidate genes identified by the exome sequencing of the patients CSL16NG. 920 
Patient Chr. Position Genotype Gene 
Mutation 
type 
Nucleotide 
change 
Amino-acid 
change 
CSL16NG 3 184104702 Het CHRD ns c.G2266A p.D756N 
CSL16NG 3 184103873 Het CHRD ns c.C1858T p.R620W 
CSL16NG 5 82554363 Het XRCC4 fs del c.760delG p.D254fs 
CSL16NG 5 82500668 Het XRCC4 sg c.673T p.R225* 
CSL16NG 9 35906600 Hom HRCT1 fs ins c.316_317insA p.P106fs 
CSL16NG 11 1266064 Het MUC5B ns c.A7963G p.I2655V 
CSL16NG 11 1247871 Het MUC5B ns c.G226T p.V76L 
CSL16NG 19 1863385 Hom KLF16 ns c.G112A p.A38T 
Abbreviations used in this table: Chr., chromosome; Position, refseq position of the 921 
variant; Genotype, Hom / homozygous, Het / heterozygous; Gene, gene symbol in which 922 
the variant is located; Mutation type, ns / nonsynonymous missense, fs del / frameshift 923 
deletion, fs ins / frameshift insertion, sg / stop gain; Nucleotide change, base change and 924 
base number resulting from the observed variant; Amino acid change, amino acid change 925 
and codon number resulting from the observed variant.  926 
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Table S2. Blood immunological tests on CSL16NG 927 
Immunological parameter Value Age-related normal range 
CD3 1973 cells/l (690-2540) 
CD4 1210 cells/l (410-1590) 
CD8 744 cells/l (190-1140) 
CD19 615 cells/l (90-660) 
CD16/56 1506 cells/l (90-590) 
CD45RACD27 200 cells/l  
TCRαȕ 98%  
TCRȖδ 2%  
CD27-IgM+IgD+ 85%  
CD27+IgM+IgD+ 5%  
CD27+IgM-IgD- 7%  
IgM 1.66 g/L (0.71-2.30) 
IgA 1.26 g/L (0.64-2.97) 
IgG 7.7 g/L (5.8-15.4) 
  928 
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Table S3. Primers used for allele-specific amplification. 929 
Primer designation Primer sequence 
XRCC4-F 5’-GTGTGAGTGCTAAGGAAGCTTTGG-γ’ 
XRCC4-WT-R 5’-TACTCTCATCATAGACTGGATCTCG-γ’ 
XRCC4-ter-R 5’-TACTCTCATCATAGACTGGATCTCA-γ’ 
XRCC4-com-R 5’-GTACTCTCATCATAGACTGGATCTC-γ’ 
XRCC4-R 5’-CTTCTGGGCTGCTGTTTCTCAGAG-γ’ 
XRCC4-WT-F 5’-TTCAGCTGCTGTAAGTAAAG-γ’ 
XRCC4-fs-F 5’-TTCAGCTGCTGTAAGTAAAA-γ’ 
XRCC4-com-F 5’-CTTCAGCTGCTGTAAGTAAA-γ’ 
  930 
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Supplemental Figures 931 
Figure S1 Construction of XRCC4 mutants  932 
(A) Sequence validation of constructed pLenti-6.3-XRCC4-Del and 933 
pLenti-6.3-XRCC4-Fs plasmid DNA. Red arrows indicated mutation sites. (B) 934 
Sequence validation of constructed pLenti-6.3-XRCC4-W43R plasmid DNA. 935 
 936 
Figure S2. CSL16NG cells display normal NER activity 937 
(A) Recovery of RNA synthesis (RRS) and (B) unscheduled DNA synthesis (UDS) are 938 
normal in CSL16NG. Nucleotide excision repair (NER)-proficient normal 48BR and 939 
-deficient XP15BR cells were used as controls. (XP represents xeroderma pigmentosum, 940 
a human disorder caused by NER-deficiency. XP causes sensitivity to ultraviolet (UV) 941 
irradiation and not to ionising radiation). Filled bars, 12 J/m2 of 254 nm UV-C; open 942 
bars, no UV. (C) UV-sensitivity of different cell strains was determined after different 943 
doses of UVC irradiation, and their viability measured by their ability to incorporate 944 
EdU (5 μM, 1 h incubation) 24 hours after treatment. (D) Normal expression levels of 945 
the CSB and XPG proteins in CSL16NG cells. (E) Quantitation of data in (D). N.S., no 946 
statistically significant difference. All primary cell lines used were between 16 and 20 947 
passages following establishment from a skin biopsy. 948 
 949 
Figure S3. Expression of the XRCC4 pathogenic alleles in CSL16NG cells 950 
(A) Capillary Sanger sequencing confirmed that the patient is compound heterozygous 951 
for the c.673C>T in XRCC4 exon 6, resulting in the premature stopgain p.R225* 952 
(inherited from the mother) as well as for the c.760delG in XRCC4 exon 7, causing the 953 
frameshift p.D254fs*68 (inherited from the father). The altered amino acids are shown 954 
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in red. (B) Locations of the primer sets used for the qRT-PCR experiments are depicted. 955 
(C) Selective quantitative amplification of the WT and the mutational p.Arg225* 956 
XRCC4 alleles in CSL16NG, and normal 48BR cells. Allele-specific primers selectively 957 
amplify the WT (c.673C) allele (XRCC4-F and XRCC4-WT-R, left panel), the 958 
pathogenic mutant (c.673C>T) allele (XRCC4-F and XRCC4-ter-R, middle panel), and 959 
both alleles at once (XRCC4-F and XRCC4-com-R, right panel). (D) Selective 960 
quantitative amplification of the WT and the mutational p.Asp254fs*68 XRCC4 alleles 961 
in CS16LNG, and normal 48BR cells. Allele-specific primers selectively amplify the 962 
WT (c.760G) (XRCC4-WT-F and XRCC4-R, left panel), the pathogenic mutant 963 
(c.760del) allele (XRCC4-fs-F and XRCC4-R, middle panel), and both alleles at once 964 
(XRCC4-com-F and XRCC4-R, right panel). Transcripts from the HPRT1 gene were 965 
used as a quantification control. All primary cell lines used were between 16 and 20 966 
passages following establishment from a skin biopsy. 967 
 968 
Figure S4 Range of radiosensitivity observed in normal patients. 969 
Figure 2A shows the sensitivity of CSL16NG primary fibroblasts relative to control 970 
cells. To confirm that the sensitivity of CSL16NG cells lies outside of the normal range, 971 
we firstly compared the sensitivity to 1BR.3 and 48BR primary fibroblasts, both of 972 
which are derived from a healthy individual. The sensitivity of 48BR cells was similar 973 
to that shown by 1BR.3 cells. To assess the magnitude of sensitivity of a broader range 974 
of individuals, we included the analysis of the most recent 20 primary fibroblasts lines 975 
from individuals whose cells were sent to our laboratory for analysis. These individuals 976 
had a range of clinical features, including aspects of immunodeficiency. We excluded all 977 
cell lines where we had an identified genetic defect. Since these cell lines were from 978 
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non-healthy individuals, we excluded the two most sensitive lines, considering that they 979 
might be from individuals with minor genetic defects affecting radiosensitivity, 980 
resulting in the analysis of 90% of this patient subset, which we considered might 981 
represent the response of a 90% percentile. The figure shows the range of sensitivity 982 
displayed by these 18 cell lines. The response of 1BR.3 and 48BR lies within this range.  983 
The lower edge of this range may be slightly more sensitive than the true responses of 984 
healthy individuals since our 18 patients were individuals with health issues. CSL16NG 985 
cells were substantially outside of this normal range. 986 
 987 
Figure S5. Increased microhomology usage at S-S junctions from CSL16NG 988 
(A) Schematic picture showing regions encoding IgM (C) and IgA (C) on IGH locus. 989 
An S-S junction created after switching from IgM to IgA is depicted below. (B) 990 
Switch fragments from either control (C369) or patient (CSL16NG) aligned with 991 
germline S and S sequences are shown. Determination of repair pattern was 992 
performed as previously described.25. Repair by direct end-joining is designated by 993 
straight line, small insertion is underlined and microhomology-based end-joining is 994 
marked by a box. The positions of break points in germline S regions are indicated by 995 
▼ or ▲.  996 
 997 
Figure S6 Ectopic expression of the XRCC4 mutant proteins  998 
(A) Schematic representation of human full-length XRCC4 and XRCC4 mutants used 999 
for the complementation analyses. The light blue box indicates an aberrant C-terminal 1000 
68 amino acids (aa). (B) Percentages of XRCC4 expressing cells were confirmed by 1001 
immunofluorescent staining of the V5-tagged proteins. 1002 
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 1003 
Figure S7. XRCC4 cDNA complements the DSB repair defect (53BP1) 1004 
(A, B) 1BR.3 normal, and CSL16NG hTERT immortalized fibroblasts were transfected 1005 
with GFP-tagged full-length XRCC4 cDNA (XRCC4-Wt) or mutant XRCC4 1006 
(XRCC4-Fs). 24 hours after transfection, cells were irradiated with γ Gy Ȗ-rays, and the 1007 
number of 53BP1 foci in GFP-positive cells was enumerated at 0.25 and 8 hours. 1008 
Substantial correction of the DSB repair defect of patient cells was observed upon 1009 
expression of both WT and mutant XRCC4 cDNA. No correction was observed after 1010 
transfection of XRCC4 cDNA into LIG4-defective cells. BG, background (no 1011 
irradiation); Error bars, S.D. of mean of triplicate experiments. In this experiment, the 1012 
green channel detected both 53BP1 + GFP-tagged XRCC4. It was possible to identify 1013 
defined 53BP1 foci above the background GFP signals of transfected cells although this 1014 
is difficult to convey in the images. 53BP1 foci were enumerated in untransfected (low 1015 
pan nuclear GFP signal) and in transfected (high pan nuclear signal) cells. 1016 
Untransfected 1BR.3 cells have a strong XRCC4 signal, some residual 53BP1 foci at 8 1017 
h post 3 Gy and little background GFP signal. Untransfected CSL16NG cells have a low 1018 
XRCC4 signal, elevated 53BP1 foci compared to 1BR.3 cells. Transfected CSL16NG 1019 
cells expressing WT-XRCC4 have close to a WT level of XRCC4, reduced residual 1020 
53BP1 foci and strong GFP pan nuclear staining. Transfected CSL16NG cells 1021 
expressing XRCC4-Fs showed a good nuclear staining of XRCC4 as well as some 1022 
cytoplasmic staining, a strong pan nuclear signal of GFP and a number of 53BP1 foci 1023 
that was slightly higher than that shown in cells expressing WT-XRCC4. The 1024 
enumeration of 53BP1 foci in untransfected 1BR.3 or CSL16NG cells was similar to 1025 
that observed in other experiments using these cells. 1026 
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 1027 
Figure S8. Proteasomal degradation of the endogenous XRCC4-Fs mutant protein 1028 
(A) Normal 48BR and CSL16NG cells were treated with CHX (100 μg/ml), MG1γβ (β0 1029 
μM), or with epoxomicin (1 μM) for 1β hours. Immunofluorescent staining was 1030 
conducted using mouse anti-XRCC4 antibody (C4, Green). DAPI, DAPI staining 1031 
(Blue); Merge, merged picture; Alexa 488 only, staining only with Alexa fluor 1032 
488-conjugated secondary antibody; Scale bar, 100 μm. (B) 48BR and CSL16NG cells 1033 
were treated with MG1γβ (β0 μM) for 1β hours, the total cell lysates were subjected to 1034 
SDS-PAGE and Western Blotting analysis using anti-XRCC4 or anti-DNA Ligase IV 1035 
antibodies. 1036 
 1037 
Figure S9. CSL16NG defects in DSB repair  1038 
(A) Normal 1BR.3 and CSL16NG primary fibroblasts were irradiated with 0.5 Gy -ray. 1039 
The average number of H2AX foci was enumerated at the indicated times. Results 1040 
represent the mean +/- S.D. of 3 experiments. (B) Normal 48BR, CSL16NG, 2BN 1041 
(XLF-defective) and 2303 (LIG4 syndrome) cells were untreated or treated with 3 Gy 1042 
-ray and incubated for 8 days to allow DSB repair. H2AX foci were enumerated at the 1043 
indicated times. Results represent the mean +/- S.D. of 3 experiments (C) Normal 48BR 1044 
and CSL16NG cells were treated with 3 Gy -irradiation and incubated with or without 1045 
the 0.5 M PARP inhibitor (KU58958, a kind gift from AstraZeneca) or 5 mM 1046 
DNA-PK inhibitor (NU7441, Stratech Scientific, UK) for the indicated times. (D) Left 1047 
panel, knockdown of LIG4 in CSL16NG hTERT cells shows an additive DSB repair 1048 
defect demonstrating that there is residual NHEJ activity. “+ LigIV kd” represents 1049 
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knockdown of LIG4 prior to IR and H2AX analysis; Right panel images show two 1050 
cells (top image, DAPI; 2nd image, H2AX; 3rd and 4th image, LIG4). The cell with a 1051 
solid asterisk has undergone knockdown, the other has not. The cell with knockdown 1052 
has a greater level of DSBs remaining as shown by intense H2AX staining. The bottom 1053 
image has been amplified to show enhanced intensity of staining. This image shows that 1054 
even in the knocked down CSL16NG hTERT cells, there is residual detectable LIG4. 1055 
Thus, the residual DSB rejoining is most likely still attributable to residual NHEJ. All 1056 
primary cell lines used were between 5 and 9 passages following establishment from a 1057 
skin biopsy. Error bars in panels A and B represent S.D. obtained from triplicate 1058 
experiments. Where only two experiments were carried out (C and D) individual 1059 
experiments have been plotted side by side. 1060 
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Abstract 29 
Background: Non-homologous end-joining (NHEJ) is the major DNA double strand 30 
break (DSB) repair mechanism in human cells. The final rejoining step requires DNA 31 
ligase IV (LIG4), together with partner proteins, XRCC4 and XLF. Patients mutated in 32 
genes encoding LIG4, XLF or other NHEJ proteins DNA-PKcs and Artemis are DSB 33 
repair defective and immunodeficient, due to the requirement for NHEJ during V(D)J 34 
recombination. 35 
Objective: We found a patient displaying microcephaly and progressive ataxia but a 36 
normal immune response. We sought to determine pathogenic mutations and to describe a 37 
molecular pathogenesis of the patient. 38 
Methods: We performed NGS exome sequencing. We evaluated DSB repair activities and 39 
V(D)J recombination capacity of the patient cells as well as a standard blood 40 
immunological characterisation. 41 
Results: We identified causal mutations in the XRCC4 gene. The patient cells are 42 
radiosensitive and display the most severe DSB repair defect that we have encountered 43 
using patient derived cell lines. In marked contrast, a V(D)J recombination plasmid assay 44 
revealed that the patient cells did not display the junction abnormalities that are 45 
characteristic of other NHEJ-defective cell lines. The mutant protein can interact 46 
efficiently with LIG4 and functions normally in in vitro assays and when transiently 47 
expressed in vivo. However, the mutation makes the protein unstable and it undergoes 48 
proteasome-mediated degradation. 49 
Conclusion: Our findings reveal a novel separation of impact phenotype: there is a 50 
 4 
pronounced DSB repair defect and marked clinical neurological manifestation but no 51 
clinical immunodeficiency. 52 
53 
 5 
Capsule Summary 54 
A patient with mutations in the XRCC4 gene, encoding a DNA double-strand-break 55 
(DSB) repair factor, displayed severe radiosensitivity and neurological abnormalities but 56 
maintained normal V(D)J recombination function. Our findings suggest a separation of 57 
impact phenotype. 58 
 59 
Key Words 60 
DNA double strand break (DSB) repair; non-homologous end joining (NHEJ); DSB 61 
repair-deficiency; XRCC4/LIG4; immunodeficiency; microcephaly 62 
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Abbreviations 64 
NHEJ: Non-homologous end-joining 65 
CSR: Class switch recombination 66 
CID/SCID: Combined or severe combined immunodeficiency 67 
DSB: DNA double strand break 68 
hTERT: Human telomerase reverse transcriptase 69 
RRS: Recovery of RNA synthesis 70 
UDS: Unscheduled DNA synthesis  71 
RDS: Recovery of DNA synthesis 72 
NMD: Nonsense mediated mRNA decay 73 
PARP: poly ADP ribose polymerase  74 
NER: Nucleotide excision repair 75 
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 77 
Introduction 78 
DSBs arise from oxidative damage and during processes such as meiosis or V(D)J 79 
recombination. They are also the major lethal lesions generated in cellular DNA by 80 
ionizing radiation. Although DSBs do not arise at high frequency endogenously, they are 81 
a critical lesion causing cell death or carcinogenesis if misrepaired. Additionally, the 82 
development of the immune response involves the introduction of DSBs to generate the 83 
requisite genetic diversity.1 V(D)J recombination represents one such process.2 Class 84 
switch recombination (CSR), which involves the switching of immunoglobulin isotypes, 85 
also involves the introduction and rejoining of DSBs.3 86 
NHEJ is the major DSB repair process in mammalian cells. The process is 87 
initiated by the binding of the Ku heterodimer to double-stranded DNA ends followed by 88 
the recruitment of the DNA-dependent protein kinase catalytic subunit, DNA-PKcs, 89 
generating the DNA-PK holoenzyme and activating DNA-PK activity.4 DNA-PK has a 90 
role in end-tethering and regulates steps of end-processing. The final step of rejoining 91 
involves the recruitment of a ligation complex encompassing DNA ligase IV (LIG4), 92 
XRCC4 and XLF. LIG4 and XRCC4 interacts strongly via a tandem BRCT domain in 93 
LIG4 and a coiled coil region in XRCC4, forming a highly stable complex.5, 6 XRCC4 is 94 
required for LIG4 stabilisation but recent findings have shown an excess of XRCC4 95 
relative to LIG4.7 Mutations that abolish LIG4/XRCC4 interaction prevent all NHEJ 96 
activity. XLF is a weaker binding partner. XRCC4 and XLF are structurally similar; both 97 
have a globular head domain, but the coiled coil region of XLF is shorter than that in 98 
XRCC4.8, 9 Recent studies have reported that dimers of XRCC4 and XLF interact to form 99 
long superhelical filaments in solution, which have been proposed to promote 100 
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end-tethering or end-bridging downstream of the DNA-PK complex.8, 10-12 101 
 Loss of LIG4 or XRCC4 confers embryonic lethality in mice due to extensive 102 
neuronal apoptosis.13, 14 In contrast, XLF null mice are viable and do not show marked 103 
immunodeficiency.15 Mutations in LIG4, DCLRE1C (Artemis), NHEJ1 (XLF) and 104 
PRKDC (DNA-PKcs) in patients have been described.16-20 LIG4 syndrome, which is 105 
caused by hypomorphic mutations in LIG4, is characterised by growth delay, 106 
microcephaly, and combined or severe combined immunodeficiency (CID/SCID). LIG4 107 
syndrome cell lines show radiosensitivity, diminished ability to repair DSBs and impaired 108 
V(D)J recombination. XLF defective patients, some of which have null mutations, 109 
display features similar to, although often more severe than LIG4 syndrome.18 Given the 110 
close interaction and requirement of XRCC4 for LIG4 stability, the expectation was that 111 
XRCC4 deficiency in patients would resemble LIG4 syndrome. 112 
 In contrast to this expectation, an XRCC4-deficient patient, CSL16NG, whose 113 
cellular defects we describe in this paper, displayed unique clinical features similar to 114 
those of Cockayne Syndrome, namely progressive neuronal degeneration including the 115 
onset of ataxia, but no clinical immunodeficiency. Our cellular analysis revealed that the 116 
mutational changes result in substantially reduced levels of XRCC4 protein, a marked 117 
defect in DSB repair but seemingly efficient V(D)J recombination. Based on comparative 118 
studies with LIG4 and XLF deficient cell lines, our results reveal a separation of impact 119 
phenotype where marked deficiency in radiation-induced DSB repair capacity can be 120 
uncoupled from defective V(D)J recombination. Our results give novel insights into the 121 
roles of XRCC4 during DSB repair.  122 
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Methods 123 
Human studies 124 
Patient and control samples were obtained with local ethical approvals [University of 125 
Sussex Research Ethics Committee; Nagasaki University Ethical, Legal and Social 126 
Implications (ELSI) committee; Ethics committee for human genome studies in 127 
Research Institute of Environmental Medicine, Nagoya University]. Written informed 128 
consent was obtained from the patient. 129 
 130 
Exome sequencing and bioinformatics 131 
Details are described in Supplementary Methods. Briefly, genomic DNA prepared 132 
from CSL16NG fibroblasts was enriched using the SureSelect All Exon Kit v5 (Agilent), 133 
followed by sequencing on the Illumina Hiseq 2500 sequencer. The sequence data were 134 
analysed by a standard exome pipeline. According to a recessive inheritance model, we 135 
selected genes that carried at least one novel deleterious homozygous or more than two 136 
heterozygous changes in one gene locus (Table S1). 137 
 138 
Cell cultures 139 
Human primary or hTERT immortalized fibroblasts were derived from the XRCC4 140 
patient (CSL16NG), LIG4 patients (F07/614, 180BR, 411BR, 2303 and 495GOS), XLF 141 
patients (2BN and F07/402), an XP patient (XP15BR) or healthy donors (1BR.3 and 142 
48BR). All primary fibroblasts were cultured in Dulbecco′s Modified Eagle Medium 143 
(DMEM) or Modified Eagle Medium (MEM), supplemented with 10-15 % fetal bovine 144 
serum (FBS) and 1× penicillin-streptomycin (PS). HEK293FT cells (Invitrogen) were 145 
grown in DMEM supplemented with 10 % FBS, 1× PS, 5 mM L-glutamine, 0.1 mM 146 
 9 
Non-Essential Amino Acids (NEAA) and 1 mM sodium pyruvate. Human colon cancer 147 
HCT116 (RCB2979) and HCT116-XRCC4 (-/-) (RCB2981) cells were provided by the 148 
RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan. 149 
 150 
Reagents and Antibodies 151 
Antibodies used were: XRCC4 (C4 and C20, Santa Cruz Biotechnology), LIG4 (D8, 152 
Santa Cruz Biotechnology; Ab80514, Abcam; 12695-1-AP, Proteintech Group), p89 153 
(S-19, Santa Cruz Biotechnology), XPG (8H7, Santa Cruz Biotechnology), CSB (Bio 154 
Matrix Research), V5-tag (MBL), Flag-tag (MBL), Actin (Ab8227, Abcam), 155 
Alpha-tubulin (Invitrogen), XLF (ab33499, Abcam; FL-299, Santa Cruz Biotechnology), 156 
53BP1 (Bethyl) and gamma H2A.X (ser139, Millipore). MG132, E64D, 157 
3-Methyladenine (3-MA), Epoxomicin, and Cycloheximide (CHX) (Sigma-Aldrich). 158 
 159 
Quantitative RT-PCR 160 
Details are as described previously.21 Total RNA was extracted using the RNeasy Plus 161 
Mini Kit (QIAGEN). The High-capacity RNA-to-cDNA kit (Applied Biosystems) was 162 
used for 1st strand synthesis. Quantitative PCR was performed using the Thermal 163 
Cycler Dice Real-Time system (TaKaRa Bio) with a QuantiTect SYBR Green PCR Kit 164 
(QIAGEN). For each sample, the relative mRNA expression levels were normalized 165 
using the HPRT1 gene. Error bars represent the S.D. of means of triplicate experiments. 166 
 167 
Lentivirus experiments 168 
Details are as described previously.22 Recombinant lentivirus particles expressing 169 
XRCC4 and its mutants were produced. Human XRCC4 cDNA was cloned in frame 170 
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with a C-terminal V5-tag in the pLenti6.3-V5-D-TOPO vector to generate 171 
pLenti6.3-XRCC4-V5 plasmid. The truncation mutant (XRCC4-Del), the frameshift 172 
mutant (XRCC4-Fs), and the single amino-acid substitution mutant (XRCC4-W43R) 173 
were generated from pLenti6.3-XRCC4-V5 by site-directed PCR mutagenesis. 174 
Sequences of the mutant plasmids were confirmed by Sanger sequencing (Figure S1). 175 
48 hours after lentivirus infection, 10 μg/ml of blasticidin (Sigma-Aldrich) was added to 176 
the medium for selection of XRCC4 stably expressing cells. 177 
 178 
Ionizing irradiation and H2AX foci assay 179 
Cells were seeded in 3 cm dishes or in 96-well plates (BD Falcon) and γGy Ȗ-ray 180 
irradiated using a 137Cs Ȗ-ray source at a dose rate of 0.017 Gy s-1, then further cultured 181 
for indicated time periods. Cells were fixed with 4 % formaldehyde and permeabilized 182 
with 0.2 % TritonX-100, followed by staining with DAPI and ȖHβAX antibody. Image 183 
acquisition and analysis were performed using the Cellomics ArrayScan VTI (Thermo 184 
Scientific). The average number of separate ȖHβAX foci was assessed on at least γ00 185 
cells. 186 
 187 
NHEJ-, V(D)J- and CSR assays 188 
The assays were performed as previously described.23, 24 For NHEJ-assay, 1 g 189 
PDVG94 plasmid, digested with EcoRV and Eco47III (Promega) to create blunt ends 190 
with 6 bp repeats, were transiently transfected into fibroblast cells using Turbofect 191 
(Fermentas). 48 h after transfection, cells were harvested and DNA extracted using 192 
DNeasy blood and tissue kit (QIAGEN). The recombined junctions were PCR amplified 193 
with primers FM30 and DAR523 and the PCR product was gel purified using Qiaquick 194 
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gel extraction kit (QIAGEN), cloned into pGEM-T vectors and sequenced (Macrogen). 195 
The V(D)J-assay was performed as the NHEJ-assay except that in total 1.5g of 196 
PDVG93 circular plasmid, RAG1 and RAG2 plasmids were transiently transfected into 197 
fibroblast cells and the coding junctions were amplified by a nested PCR using the 198 
primers NV05F (5’-CTATAGGGGAATTGTGAGCGGATAACDG-γ’), DG147 and 199 
DG89, FM30.23 Switch recombination junctions were PCR amplified, cloned, 200 
sequenced and analysed as described previously.25, 26 201 
 202 
Protein purification  203 
Detailed protein purification procedures and buffer conditions are as described 204 
previously.21, 27 Briefly, HEK293FT cells were co-transfected with the 205 
pLenti6.3-LIG4-His and pLenti6.3-Flag-XRCC4, or its mutants. Cell lysates were 206 
incubated with anti-Flag M2 beads (Sigma-Aldrich) for 4 hours at 4 °C. After extensive 207 
washing of the beads, the Flag-tagged wild type (WT) or mutant XRCC4 in complex 208 
with LIG4 was eluted with Flag-peptide. The eluted complexes were dialyzed, 209 
concentrated and stored at -80°C. For expression and purification of GST-XLF protein, 210 
E.coli BL21 (DE3) cells were transformed with pGEX6-GST-XLF plasmid. The 211 
GST-XLF protein was induced with IPTG. The cells were harvested, lysed and cleared 212 
lysate was loaded onto a GSTrap HP column (GE Healthcare). After washing, the 213 
GST-XLF protein was eluted by reduced L-glutathione (Wako). The eluted proteins 214 
were dialyzed, concentrated and stored at -80°C. 215 
 216 
In vitro DSB ligation assay 217 
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A 934 bp Cy5-labeled double strand DNA fragment was PCR amplified from 218 
pEGFP-C3 vector using a set of primers (Forward: 219 
5’-Cy5-GTTTCGCCACCTCTGACTTGAGCG-γ’; Reverse: 220 
5’-GAACTTCAGGGTCAGCTTGCCGTAG-γ’). The DNA fragment was digested with 221 
NcoI (TaKaRa). A 545 bp fragment (Cy5 labeled at the 5’ blunt-end and a γ’-overhang 222 
end) and a 255 bp fragment (with 4 bp overhangs at each end) were purified. The 223 
complexes were incubated for 30 min at 37 °C in a 30 l reaction mixture (66 mM 224 
Tris-HCl pH7.5, 5 mM MgCl2, 1 mM DTT, 1 mM ATP) with 50 ng of DNA substrates 225 
(the Cy5-labeled 545 bp fragment: the unlabeled 255 bp fragment = 2: 3). Reaction 226 
mixtures were pre-incubated for 10 min on ice with GST-XLF, and then LIG4-XRCC4 227 
complex was added at 37 °C for 15 min. The reactions were terminated by adding 1.5 μl 228 
of 10 % SDS, followed by purification with QIAquick PCR Purification kit (QIAGEN). 229 
30 l of the eluted DNA was mixed with 10× loading buffer, incubated at 65 °C for 5 230 
min and cooled on ice rapidly. 15 l of the DNA was run on 1 % agarose gel and 231 
analyzed by the Typhoon imager (GE Healthcare). 232 
 233 
Analysis of protein stability 234 
HEK293FT cells were transiently transfected with XRCC4 or its mutant plasmids. Cells 235 
were treated with CHX (100 μg/ml) combined with MG1γβ (β0 μM), E64D (β0 μM), 236 
Epoxomicin (1 μM) or γ-MA (10 mM). Cells were harvested at the indicated time 237 
points. Whole cell lysate was analysed by Western blotting using anti-V5 antibody. 238 
 239 
Immunoprecipitation 240 
Immunoprecipitation of ectopically expressed WT or mutant XRCC4 proteins in 241 
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CSL16NG cells was performed on cell extracts using anti-V5 agarose (MBL). 242 
Immunoprecipitates were washed five times with lysis buffer containing 0.15 or 1 M 243 
NaCl, then eluted using V5-peptide (2 mM, MBL). The eluted proteins were separated 244 
on 5-20 % gradient SDS-PAGE gels, blotted onto PVDF membranes and analyzed by 245 
Western blotting. 246 
 247 
Confocal Fluorescence Microscopy 248 
Cells were washed once with PBS (Wako) and fixed with Fix buffer [300 mM sucrose, 249 
2 % (v/v) formaldehyde, and 0.2 % (v/v) Triton X-100 in PBS]. After a brief washing in 250 
PBS, cells were blocked with 10 % FBS in PBS for 30 min and then incubated for 1 h 251 
with the anti-V5-tag, anti-ȖHβAX, anti-LIG4 or anti-XRCC4 antibodies at appropriate 252 
dilution. The cells were then washed three times with PBST (0.05 % Tween-20) and 253 
incubated with Alexa fluor488-conjugated secondary antibody at a dilution of 1:500 for 254 
1 h. To visualize nuclei, the cells were incubated with DAPI (10 ng/mL) for 15 min. 255 
Cells were then washed and mounted, and examined on a LSM 700 laser scanning 256 
confocal microscope (Carl Zeiss). Images were taken with the 40× oil immersion 257 
objective lens under identical imaging settings. 258 
 259 
Survival analysis 260 
Fibroblasts were irradiated using a 137Cs Ȗ-ray source at a dose rate of 0.09 Gy s-1. 261 
Radiosensitivity was assessed by colony survival analysis. Cells were trypsinised, 262 
irradiated and plated onto feeder cells prepared 24 h earlier and left to form colonies for 263 
three weeks. For XRCC4 complementation experiments, normal (48BR), CSL16NG 264 
and CSL16NG-derived fibroblasts expressing WT XRCC4 were seeded in 96-well 265 
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plates (BD Falcon). After Ȗ-ray irradiation, cells are incubated for a further 24 hours. 266 
Sensitivity to IR was measured by recovery of DNA synthesis (RDS) analysis as 267 
described in supplementary methods (RRS, UDS and RDS assays). 268 
  269 
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Results 270 
Patient CSL16NG has compound heterozygous mutations in XRCC4 271 
Patient CSL16NG, the first daughter of non-consanguineous Caucasian parents, had 272 
significant intrauterine growth failure and microcephaly at birth. She showed slow 273 
growth, delayed motor development and dysmorphic features. Her stature, 274 
developmental delay, deep-set eyes and other features resembled those of Cockayne 275 
syndrome (CS). However, she had no history of photosensitivity and relatively slow 276 
progression of symptoms. She developed progressive ataxia. At 19 years, she was 277 
diagnosed with a low-grade thalamic glioma, which was not removed. She has 278 
hyperopia, diabetes mellitus, hypothyroidism, moderate hearing loss and slurred speech, 279 
although her understanding remains good. Her neurology has been described previously 280 
(Patient 3 in28). She has no significant infectious history and no obvious signs of 281 
abnormal immune response. Detailed routine blood immunological peripheral blood 282 
tests did not reveal any abnormality. Blood cell counts including peripheral blood 283 
lymphocyte sub-type numbers, immunoglobulin IgM, IgG and IgA levels were normal. 284 
Autoantibodies were negative and specific vaccine antigen antibody responses were 285 
present (Table S2). She is currently 23 years old (Her weight is 41.4 kg (<<3rd centile), 286 
head circumference 42.5 cm (<<3rd centile) (Figure 1A). 287 
 As a diagnosis of CS was considered, cellular tests for abnormal responses to 288 
UV light were carried out on a fibroblast culture established from a skin biopsy, but no 289 
abnormality typical of CS cells was observed (Figures S2A-C). Heterozygous 290 
mutations in two CS-related genes (ERCC6/CSB and ERCC5/XPG) were identified but 291 
both alleles were inherited from the asymptomatic father. Both proteins were expressed 292 
at normal levels (Figures S2D and S2E). Whole exome sequencing was carried out and 293 
 16 
of the five potentially pathogenic candidate genes identified (details are described in 294 
Supplemental Method; Tables S1) XRCC4 was the strongest. One mutation (c.C673T, 295 
p.R225*) introduced a premature stop codon; the second mutation (c.G760del, 296 
p.D254fs*68) was a frameshift (Figure S3A, confirmed by Sanger gDNA sequencing), 297 
which predicted the expression of a protein with an aberrant C-terminal 68 amino acids 298 
(aa), resulting in a 322 aa protein (normal full-length protein has 334 aa). 299 
 Allele-specific quantitative RT-PCR (qRT-PCR) using primers that selectively 300 
amplify the wild type (WT) or the mutant XRCC4 cDNAs (Figure S3B and in Table 301 
S3) revealed extremely low expression of the p.R225* allele, consistent with strong 302 
nonsense mediated mRNA decay (NMD) caused by the premature stop codon (Figure 303 
S3C, middle panel; Figure S3D, left panel). The other allele encompassing the 304 
p.D254fs*68 frameshift mutation (designated as XRCC4-Fs hereafter) was expressed at 305 
~30% of the total XRCC4 expression level in normal 48BR cells (50% would be 306 
expected if fully expressed from one allele). The small decrease in the frameshift 307 
transcript level could reflect some NMD, although we note that the newly generated 308 
premature termination codon is located in the last exon, which does not normally trigger 309 
NMD. The mutational change could additionally affect the splicing efficiency or 310 
accuracy, which may also cause NMD (Figure S3D, middle panel; Figure S3C, left 311 
panel). No detectable XRCC4 was observed by immunoblotting of CSL16NG cells 312 
using a mouse anti-XRCC4 antibody with an epitope located close to the N-terminus of 313 
XRCC4 (Figure 1B). We could detect XRCC4 from a control fibroblast diluted ten-fold 314 
arguing that there is less than 10% of the normal level of XRCC4 in the patient cells. 315 
 XRCC4 is reported to co-stabilise LIG4.5, 29, 30 Consistently, LIG4 was 316 
significantly reduced in CSL16NG fibroblasts assessed by immunoblotting (Figure 1B, 317 
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1C). The level of LIG4 appeared to vary depending on conditions and antibody (see 318 
Figure 1B, 2nd and 3rd panel). When compared with the LIG4-null cell line N114P2 319 
(LIG4-/-), a band of LIG4 was clearly visible (Figure 1C) and, from the results of many 320 
experiments, we estimate a residual level of between 5 and 15% of normal. We also 321 
analysed XRCC4 expression by immunofluorescence (IF), which revealed a low signal 322 
in CSL16NG cells detectable in both the cytoplasm and nucleus (Figure 1D). 323 
 324 
CSL16NG cells are radiosensitive and DSB repair defective. 325 
CSL16NG primary fibroblasts showed marked radiosensitivity relative to control cells 326 
(Figure 2A and Figure S4) and reduced recovery of replication after radiation exposure 327 
(Figure 2B). Further, CSL16NG cells showed diminished DSB repair capacity, assessed 328 
by enumerating H2AX foci (Figure 2C, compare red and white bars). In order to 329 
confirm that these defects are attributable to the mutation in XRCC4, we analysed the 330 
ability of WT XRCC4 to correct the defect in CSL16NG cells. When lentivirus 331 
expressing XRCC4-Wt cDNA was used to infect CS16LNG cells, both the ability to 332 
synthesise DNA after irradiation (Figure 2B) and the repair of DSBs (Figure 2C, green 333 
bars) were restored to normal levels. 334 
 335 
CSL16NG cells are defective in a plasmid DSB rejoining assay 336 
We next examined the fidelity of repair in CSL16NG cells using an NHEJ end-joining 337 
assay that involved transfection of CSL16NG cells and control cells with linearised 338 
blunt end plasmids encompassing a 6 bp identical repeat at both DNA ends.23 Whereas 339 
the junctions from control cells were preferentially repaired by direct end-joining, this 340 
type of repair was nearly absent in CSL16NG cells (2 % vs 72 % in control, Table 1). 341 
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Instead, the repair of CSL16NG cells was mediated by the usage of 6 bp 342 
microhomology (78 % vs 8 % in controls) at the junctions, consistent with the loss of 343 
efficient NHEJ in CSL16NG cells. A similar skewed repair pattern has previously been 344 
observed in XLF-deficient cells.24 These findings demonstrate a marked impact of the 345 
mutation on the fidelity of DSB repair. 346 
 347 
CSL16NG cells carry out V(D)J recombination with enhanced fidelity compared to 348 
control cells 349 
Defects in NHEJ are usually associated with immunodeficiency. Surprisingly, 350 
CSL16NG has no history of chronic infections, and clinical analysis verified a normal 351 
immune response (see above). To assess the capacity of CSL16NG cells to carry out 352 
V(D)J recombination, we co-transfected CSL16NG cells with RAG1/2 expressing 353 
plasmids together with a V(D)J substrate and assessed the fidelity of recombination.23 354 
Strikingly, in contrast to the NHEJ assay, most coding junctions were accurately 355 
rejoined with little use of microhomology or deletion formation (Table 2). This novel 356 
V(D)J recombination phenotype contrasts with the pattern obtained with cell lines 357 
derived from most LIG4 syndrome and XLF-deficient patients, where coding junctions 358 
are characterized by increased deletions and microhomology usage.16, 18, 23, 31 359 
 360 
CSL16NG cells show altered repair pattern during class switch recombination 361 
To assess class switch recombination (CSR), we examined peripheral blood 362 
mononuclear cells (PBMC) from CSL16NG. The patient was aged 22 when tested, thus 363 
we compared her CSR junctions to our previously published 154 S-S junctions from 364 
healthy adults (Table 3, Figure S5). Amplification of S-S junctions from in vivo 365 
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switched B lymphocytes from the patient revealed a reduced frequency of junctions 366 
repaired by direct end-joining, albeit not to a significant degree (5% vs. 18% in controls, 367 
2, p=0.15), and a markedly increased frequency of repair by unusually long 368 
microhomologies (≥10 bp; γ6% vs. γ% in controls). The altered pattern was similar to, 369 
but less prominent than that previously observed in XLF and LIG4 deficient patients.24, 370 
32
 Thus, although the patient has a normal level of serum IgA, the altered pattern of the 371 
CSR junctions still clearly suggests a defect in the recombination process, which relies 372 
on the classical NHEJ machinery. 373 
 374 
Effect of XRCC4-Fs mutation on XRCC4 function 375 
We next examined the impact of XRCC4-Fs on XRCC4 function and protein expression. 376 
We also examined two other forms of XRCC4 protein (Figure S6A): XRCC4-Del has a 377 
stop codon at the position of the frameshift mutation in CSL16NG, and thus lacks the 378 
C-terminal aberrant polypeptide. XRCC4-W43R, contains an amino acid substitution 379 
p.W43R previously identified in a primordial dwarfism (PD) patient.33 Although Trp43 380 
is conserved, there is no current evidence for causality. Following lentivirus infection as 381 
described above, we found that all forms of the protein were expressed (Figure S6B). 382 
Strikingly, normal DSB-repair activity was restored, not only by expression of WT 383 
XRCC4, but also by XRCC4-Fs. Further, XRCC4-Del also complemented the 384 
CSL16NG DSB repair defect whereas XRCC4-W43R showed little complementation 385 
(Figure 2C, purple, blue and orange bars). Lentiviral expression results in XRCC4 386 
overexpression. To examine DSB repair under physiological expression levels, we also 387 
used hTERT-immortalised CSL16NG cells in a plasmid based complementation assay 388 
(Figure S7) and measured DSBs as 53BP1 foci in cells containing the plasmid. Full 389 
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complementation was found using WT XRCC4 protein and substantial, although not 390 
full, correction by XRCC4-Fs (Figure S7B). Untransfected cells in the same population 391 
showed the expected DSB repair defect. 392 
 These findings suggest that the mutant protein can partially function in DSB 393 
repair. This function likely contributes to the residual DSB repair capacity observed in 394 
CSL16NG cells. We also conclude that the W43R mutation impairs XRCC4 function. 395 
 396 
Biochemical characterisation of the mutant XRCC4 proteins 397 
To further examine the functional capacity of XRCC4-Fs, we purified recombinant 398 
XRCC4-LIG4 complexes and examined their activity in vitro. Flag-tagged XRCC4-Wt, 399 
XRCC4-Fs, and XRCC4-Del proteins were co-expressed with WT His-tagged LIG4 in 400 
HEK293FT cells and co-purified by affinity chromatography (Figure 3A; GST-XLF 401 
was purified from E.coli in Figure 3B). XRCC4-Fs and XRCC4-Del formed complexes 402 
with LIG4, demonstrating that the XRCC4 C-terminus is dispensable for complex 403 
formation. 404 
 In vitro ligation assays were performed using a fluorescent-labeled double 405 
strand DNA with a 3' overhang on one side and an additional smaller double strand 406 
DNA substrate with the same 3' cohesive overhang on both sides (Figure 3C). The 407 
ability of the XRCC4-Fs and XRCC4-Del mutants to support LIG4-mediated ligation 408 
was indistinguishable from that of the XRCC4-Wt. Further, the activity was efficiently 409 
stimulated by XLF. We conclude that the effect of these alterations on the XRCC4/LIG4 410 
enzyme activity is relatively minor. This finding explains the substantial 411 
complementation when the mutant proteins are exogenously expressed. 412 
 413 
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XRCC4-Fs is degraded by the proteasome. 414 
Given the low levels of XRCC4-Fs observed in CSL16NG cells and its presence in the 415 
cytoplasm, we examined whether it is subject to proteolytic degradation. To assess this, 416 
we first transiently expressed WT and mutant XRCC4 in HEK293FT cells in the 417 
presence or absence of the protein synthesis inhibitor, cycloheximide (CHX). In the 418 
presence of CHX, XRCC4-Wt protein was stable up to 12 h, whereas XRCC4-Fs was 419 
significantly degraded (Figure 4A). Remarkably, the XRCC4-Del protein was as stable 420 
as XRCC4-W43R. Degradation of XRCC4-Fs was inhibited by addition of the 421 
proteasome inhibitors, MG-132 and epoxomicin (Figure 4B) but unaffected by the 422 
cysteine protease inhibitor E64D, which inhibits calpain and lysosomal proteases, or 423 
3-Methyladenine (3-MA), an autophagy inhibitor (Figure 4B). Consistent with these 424 
observations, the level of endogenous XRCC4 in CSL16NG cells was significantly 425 
enhanced by incubation in MG132 (Figure S8). These findings strongly suggest that 426 
XRCC4-Fs is subjected to proteasome mediated degradation, which provides an 427 
explanation for the very low (indeed undetectable) level of the mutant XRCC4 protein 428 
and the low level of LIG4 in the patient cells. In view of these findings, we predicted 429 
that the enhanced expression of exogenous WT or mutant XRCC4 in CSL16NG cells 430 
would lead to increased LIG4 levels. Indeed, overexpression of WT and XRCC4 mutant 431 
proteins in CSL16NG resulted in recovery of LIG4 protein levels (Figure 4C, compare 432 
lanes 3-6 with lane 2), which is consistent with the ability of XRCC4-Fs to complement 433 
the CSL16NG repair defect. 434 
 Taking the complementation analyses and the biochemical data together, we 435 
conclude that the XRCC4-Fs mutant protein can efficiently complex with LIG4 and 436 
promote DSB rejoining and that a major impact of the change is greatly reduced 437 
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XRCC4-Fs stability due to proteasomal degradation. 438 
 439 
The mutations in CSL16NG confer a separation of impact phenotype. 440 
Despite the DSB repair defect observed in CSL16NG cells and marked developmental 441 
features, the patient had a normal immune response and the patient cells showed 442 
enhanced accuracy in an in vitro assay for V(D)J recombination, in marked contrast to 443 
other NHEJ-deficient patients. A trivial explanation might be that there is sufficient 444 
residual DSB repair activity to support V(D)J recombination but not the efficient repair 445 
of radiation induced DSBs. To gain further insight, we carried out a comparative 446 
analysis of the efficiency of DSB repair of CSL16NG cells and a range of 447 
patient-derived fibroblasts with deficiencies in other NHEJ proteins (XLF or LIG4) 448 
(Figure 5A). Since LIG4 is essential, LIG4 syndrome patients have hypomorphic 449 
mutations and hence a range of clinical severities, which generally correlate with the 450 
magnitude of the repair defect.34 Importantly, most of the LIG4 Syndrome cells 451 
examined (and in total 7/8 lines previously examined by us) repaired most DSBs 452 
induced by 3 Gy IR by 72 h (Figure 5A and data not shown). (495GOS had more 453 
marked sensitivity. This line, however, had normal LIG4 protein expression, raising the 454 
possibility that the mutational change could exert a dominant negative phenotype). 455 
Except for patient 180BR,35, 36 all showed some degree of immunodeficiency. Of 456 
relevance here, the in vitro ligation activities of 411BR and cell line 2303 have been 457 
previously estimated to be < 1%, yet both lines rejoin the DSBs induced by 3 Gy within 458 
72h.34, 37 411BR has previously been shown to express normal levels of mutant LIG434, 459 
37
 but, significantly, 2303 expressed lower levels of LIG4 compared to CSL16NG 460 
(Figures 5B and 5C). Collectively, this analysis of LIG4 syndrome cell lines strongly 461 
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suggests that only a low level of residual LIG4 activity (1% or less) suffices to repair all 462 
DSBs induced by 3 Gy IR, albeit with slow kinetics, a conclusion consistent with 463 
previous findings.38 In marked contrast, CSL16NG fibroblasts, despite harbouring 464 
5-15 % residual LIG4 levels had a severe DSB repair defect. The magnitude of the DSB 465 
repair defect was similar to, although more severe than, that shown by XLF-defective 466 
cells. The repair defect was evident following exposure to a low dose of radiation (0.5 467 
Gy) and, after 3 Gy IR, 25 % of the DSBs remained unrepaired even 8 days post 468 
exposure (Figures S9A and S9B). Indeed, this represents possibly the most severely 469 
DSB repair defective human cell line that we have encountered. In rodent cells, defects 470 
in NHEJ proteins, including XLF can lead to DSB repair by alternative NHEJ 471 
(Alt-NHEJ).39 However, the residual DSB repair in CSL16NG cells is not inhibited by a 472 
PARP inhibitor, KU58958 (Figure S9C) and displays an additive repair defect 473 
following siRNA depletion of LIG4 (Figure S9D) or the addition of a DNA-PK 474 
inhibitor NU7441 (Figures S9C), suggesting that it does not represent Alt-NHEJ but 475 
residual canonical NHEJ activity. This is consistent with current evidence that 476 
Alt-NHEJ does not function in human cells unless Ku is absent.40, 41 We note also that 477 
CSL16NG cells expressed close to normal levels of XLF, as did the LIG4 syndrome 478 
cells examined (Figure 5B). 479 
 These findings show that CSL16NG has a very severe defect in repair of DSB 480 
and importantly, they suggest that the normal immune response of the patient cannot be 481 
attributed to a mild defect in DSB repair, providing evidence for a separation of 482 
function phenotype.  483 
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Discussion. 484 
We describe a patient with mutational changes in the NHEJ protein, XRCC4. The 485 
patient described here has unexpected clinical features for an NHEJ deficiency. Our 486 
detailed cellular analysis provides evidence for a separation of impact phenotype, 487 
namely severely defective DSB repair but normal immune responses, and reveals a 488 
clinical and cellular manifestation for mutations in XRCC4 that is unexpected and 489 
distinct from those conferred by diminished LIG4 enzyme activity. 490 
 In patient CSL16NG, the major expressed allele encodes a protein with 68 491 
aberrant C-terminal amino acids p.(D254fs*68). The mutant protein can interact with 492 
LIG4 and is largely functional for DSB repair in vitro and in vivo. The major impact of 493 
the mutational change is to promote proteasome mediated degradation of the mutant 494 
protein, so that CSL16NG cells have very low XRCC4 protein levels. 495 
 There are two remarkable findings from our results, with important 496 
implications. First, the defect in DSB repair is significantly greater than that of cells 497 
with lower levels of LIG4, and secondly, despite this defect, V(D)J recombination is 498 
proficient and the patient does not display any gross clinical or laboratory 499 
immunodeficiency to date. We will consider these findings in turn. 500 
DSB repair defect. Despite low XRCC4 levels, there is ~5-15 % residual LIG4 501 
localised in the nucleus. This residual activity, by comparison with LIG4 syndrome cells, 502 
is estimated to be sufficient to affect slow DSB rejoining after 3 Gy IR, yet CSL16NG 503 
cells have a dramatic DSB repair defect. These findings, therefore, strongly suggest that 504 
there must be a role for XRCC4 in DSB rejoining that is distinct from its accepted 505 
function in stabilising LIG4.  506 
Recent studies have shown that XLF forms filaments with XRCC4 and 507 
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current models propose that these function in DNA end-stabilisation during DSB 508 
repair.8, 10-12 This structural role for XRCC4 in forming filaments necessitates multiple 509 
XRCC4 molecules at each DNA end and is unlikely to be fulfilled by a low level of 510 
residual XRCC4 protein. The similar DSB repair defect between XLF-deficient and 511 
CSL16NG cells supports an overlapping role in DSB repair. Thus, we propose that the 512 
marked DSB repair defect in CSL16NG cells is a consequence of insufficient XRCC4 513 
to form filaments with XLF. In contrast, low residual LIG4, of which only 1-2 514 
molecules are likely to be required per DSB, is sufficient to allow complete DSB repair 515 
albeit with slow kinetics (Figure S9B). If this hypothesis is correct, our data provide the 516 
first evidence suggesting that XRCC4’s role in XLF filament formation can be 517 
uncoupled from its more direct role in ligation. 518 
DSB repair defect and normal immune response. Despite the marked DSB repair 519 
defect in CSL16NG cells and an altered repair pattern during CSR, the patient did not 520 
display any immunodeficiency, and in a cell based assay, V(D)J recombination took 521 
place with enhanced rather than reduced accuracy. Most LIG4 syndrome cells, including 522 
line 2303, displayed combined immunodeficiency or severe combined 523 
immunodeficiency, yet our comparative analysis of DSB repair showed that most LIG4 524 
Syndrome cells had more efficient DSB repair than CSL16NG.16 Thus the normal 525 
immune response of CSL16NG cannot be attributed solely to a mild DSB repair defect, 526 
suggesting a separation of impact phenotype. 527 
This raises the intriguing possibility that XRCC4’s role in complex with XLF 528 
in end-stabilisation may be dispensable for V(D)J recombination. XLF-deficient 529 
patients, however, do display immunodeficiency demonstrating a role for XLF in V(D)J 530 
recombination in humans.18 There appear to be distinctions between the requirement for 531 
 26 
synapsis/end-stabilisation during V(D)J recombination versus the repair of genotoxic 532 
DSBs. Indeed, XLF is dispensable for V(D)J recombination in mice where ATM, 533 
DNA-PK and 53BP1 have been proposed to have redundant roles, yet XLF deficient 534 
patients frequently display pronounced immunodeficiency.42, 43 We note that the 535 
phenotype of CSL16NG cells overlaps with that of XLF-deficient mice (ie a marked 536 
DSB repair defect but proficient V(D)J recombination).15 Additionally in mice, RAG2 537 
has been proposed to have a role in influencing rejoining during V(D)J recombination.44 538 
We note also that a recent paper identified PAXX as a new XRCC4 super-family 539 
member that functions with XRCC4 and XLF in NHEJ.45 It is possible that there could 540 
be redundancy between PAXX and XRCC4 during V(D)J recombination but not during 541 
the repair of genotoxic DSBs. Further work is required to gain insight into the 542 
mechanism underlying these intriguing findings. 543 
An additional novel phenotype of CSL16NG cells is that all the junctions 544 
formed in the V(D)J recombination assay involved high fidelity joining of the coding 545 
ends. This phenotype contrasts strongly with the lack of direct rejoining of DNA ends in 546 
the NHEJ plasmid assay and the CSR junction analysis, and further supports a 547 
separation of function phenotype. The basis for the difference from control cells in the 548 
V(D)J recombination assay, where small deletions/insertions can arise is unclear. 549 
However the accurate rejoining contrasts to other NHEJ deficient lines, which are 550 
characterised by large deletions and microhomology usage. Although the lack of 551 
junctional diversity seen in this fibroblast based assay might predict a diminished 552 
repertoire of T- and B- cells, it is possible that the assay does not fully reflect the in vivo 553 
process due to differences between fibroblasts and lymphocytes (e.g. T-cells express 554 
tdT). 555 
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Using CSL16NG fibroblasts and the assays established here, we also 556 
examined the impact of W43R, a previously described XRCC4 mutational change 557 
observed in a patient with primordial dwarfism.33 We provide evidence that W43R is a 558 
pathological mutational change, supporting the notion that homozygous expression of 559 
XRCC4-W43R underlies the primordial dwarfism observed in the patient. 560 
Several recent studies have also described patients with mutations in XRCC4.46-49 561 
Strikingly, all patients displayed microcephaly and growth delay but no overt 562 
immunodeficiency (although detailed examination of V(D)J recombination ability was 563 
not investigated in these patients). This strengthens our proposal that XRCC4 deficiency 564 
confers a separation of impact phenotype (impacting upon the repair of genotoxic DSBs 565 
but not the repair of DSBs induced during V(D)J recombination), demonstrating that 566 
this is not a finding specific to our patient. The severe DSB repair defect in CSL16NG 567 
cells also provides a potential explanation for the marked neurological phenotype 568 
observed in the patient. An unusual feature for NHEJ deficiency was the development 569 
of progressive ataxia in the patient and it is tempting to speculate that this is a 570 
consequence of persisting unrepaired DSBs. Intriguingly, a progressive neurological 571 
phenotype involving unsteady gait was recently observed in two XRCC4-deficient 572 
siblings, who similarly had no detectable residual XRCC4 protein.49 This supports the 573 
notion that progressive ataxia could be a consequence of marked XRCC4 deficiency. 574 
The prediction of our working model is that mutations in XRCC4 that result in 575 
low expression of a protein capable of interacting with LIG4 will confer marked 576 
neurological deficits without associated immune deficiency. Given the striking 577 
resemblance of patient CSL16NG, when a young child, to CS patients, XRCC4 should 578 
be considered a candidate for potential causal mutations in further patients with similar 579 
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features, including further CS-like patients with normal transcription-coupled nucleotide 580 
excision repair. 581 
In summary, we describe a patient with mutations in XRCC4. The patient had 582 
marked neurological abnormalities with progressive ataxia. Our biochemical and 583 
cellular analysis provides evidence that the mutational changes in this patient confer a 584 
separation of impact phenotype with a severe defect in DSB repair but no marked defect 585 
in V(D)J recombination. Recent papers have described additional XRCC4-deficient 586 
patients with a normal immune response.33, 46-49 As a working model, we propose that 587 
this could arise from a separation of XRCC4 function in stabilising LIG4 versus its role 588 
in forming filaments with XLF. We propose that XRCC4 is required for all DSB 589 
rejoining since LIG4 is unstable in the absence of XRCC4. However, only a low-level 590 
of protein suffices to provide sufficient LIG4 to effect slow rejoining. In contrast, 591 
XRCC4’s role in filament formation with XLF is essential for efficient rejoining of 592 
genotoxic DSBs but appears to be dispensable during V(D)J recombination in human 593 
cells, possibly due to redundancy with other proteins that can promote synapsis. 594 
 595 
  596 
 29 
Acknowledgements 597 
We are grateful to Elena Korneeva for technical assistance, Dik van Gent and 598 
Jean-Pierre Villartay for cell lines from patients, Hironori Niki for general discussions, 599 
and to the patient’s mother for much helpful clinical information. 600 
This work was supported by a foreign researcher grant from the Japan Society for the 601 
Promotion of Science (JSPS) (P14093) to C.G.; a grant for Research for overcoming 602 
intractable diseases (H26-general-046) from The Ministry of Health Labour and Welfare 603 
of Japan, KAKENHI Grants-in-Aid for Scientific Research (B) (26291005) from JSPS, 604 
KAKENHI Grants-in-Aid for Scientific Research (A) (Overseas Academic Research) 605 
(15H02654) from JSPS and a science research grant from the Uehara Memorial 606 
Foundation to T.O; KAKENHI Grants-in-Aid for Young Scientists (A) (15H05333) 607 
from JSPS, a research grant from the Uehara Memorial Foundation, a medical research 608 
grant from Daiichi-Sankyo Foundation of Life Science and a medical research grant 609 
from Takeda Science Foundation and Special Coordination Funds for Promoting 610 
Science and Technology from the Japan Science and Technology Agency (JST) to 611 
Y.Nakazawa; the Swedish Research Council and the European Research Council 612 
(242551-ImmunoSwitch) to Q.P-H. 613 
 614 
 615 
References 616 
1. Gellert M. V(D)J recombination: RAG proteins, repair factors, and 617 
regulation. Annu Rev Biochem 2002; 71:101-32. 618 
2. Alt FW, Zhang Y, Meng FL, Guo C, Schwer B. Mechanisms of 619 
programmed DNA lesions and genomic instability in the immune 620 
system. Cell 2013; 152:417-29. 621 
 30 
3. Boboila C, Alt FW, Schwer B. Classical and alternative end-joining 622 
pathways for repair of lymphocyte-specific and general DNA 623 
double-strand breaks. Advances in immunology 2012; 116:1-49. 624 
4. Radhakrishnan SK, Jette N, Lees-Miller SP. Non-homologous end 625 
joining: emerging themes and unanswered questions. DNA Repair 626 
(Amst) 2014; 17:2-8. 627 
5. Critchlow SE, Bowater RP, Jackson SP. Mammalian DNA 628 
double-strand break repair protein XRCC4 interacts with DNA ligase 629 
IV. Current Biology 1997; 7:588-98. 630 
6. Grawunder U, Zimmer D, Fugmann S, Schwarz K, Lieber MR. DNA 631 
ligase IV is essential for V(D)J recombination and DNA double-strand 632 
break repair in human precursor lymphocytes. Molecular Cell 1998; 633 
2:477-84. 634 
7. Mani RS, Yu Y, Fang S, Lu M, Fanta M, Zolner AE, et al. Dual modes of 635 
interaction between XRCC4 and polynucleotide kinase/phosphatase: 636 
implications for nonhomologous end joining. J Biol Chem 2010; 637 
285:37619-29. 638 
8. Hammel M, Rey M, Yu Y, Mani RS, Classen S, Liu M, et al. XRCC4 639 
protein interactions with XRCC4-like factor (XLF) create an extended 640 
grooved scaffold for DNA ligation and double strand break repair. The 641 
Journal of biological chemistry 2011; 286:32638-50. 642 
9. Williams GJ, Hammel M, Radhakrishnan SK, Ramsden D, Lees-Miller 643 
SP, Tainer JA. Structural insights into NHEJ: building up an 644 
integrated picture of the dynamic DSB repair super complex, one 645 
component and interaction at a time. DNA Repair (Amst) 2014; 646 
17:110-20. 647 
10. Mahaney BL, Hammel M, Meek K, Tainer JA, Lees-Miller SP. XRCC4 648 
and XLF form long helical protein filaments suitable for DNA end 649 
protection and alignment to facilitate DNA double strand break repair. 650 
Biochemistry and cell biology = Biochimie et biologie cellulaire 2013; 651 
91:31-41. 652 
11. Andres SN, Vergnes A, Ristic D, Wyman C, Modesti M, Junop M. A 653 
human XRCC4-XLF complex bridges DNA. Nucleic Acids Res 2012; 654 
 31 
40:1868-78. 655 
12. Wu Q, Ochi T, Matak-Vinkovic D, Robinson CV, Chirgadze DY, 656 
Blundell TL. Non-homologous end-joining partners in a helical dance: 657 
structural studies of XLF-XRCC4 interactions. Biochem Soc Trans 658 
2011; 39:1387-92, suppl 2 p following 92. 659 
13. Barnes DE, Stamp G, Rosewell I, Denzel A, Lindahl T. Targeted 660 
disruption of the gene encoding DNA ligase IV leads to lethality in 661 
embryonic mice. Curr Biol 1998; 8:1395-8. 662 
14. Frank KM, Sekiguchi JM, Seidl KJ, Swat W, Rathbun GA, Cheng HL, 663 
et al. Late embryonic lethality and impaired V(D)J recombination in 664 
mice lacking DNA ligase IV. Nature 1998; 396:173-7. 665 
15. Li G, Alt FW, Cheng HL, Brush JW, Goff PH, Murphy MM, et al. 666 
Lymphocyte-specific compensation for XLF/cernunnos end-joining 667 
functions in V(D)J recombination. Mol Cell 2008; 31:631-40. 668 
16. O'Driscoll M, Cerosaletti KM, Girard P-M, Dai Y, Stumm M, Kysela B, 669 
et al. DNA Ligase IV mutations identified in patients exhibiting 670 
development delay and immunodeficiency. Mol Cell 2001; 8:1175-85. 671 
17. Woodbine L, Neal JA, Sasi NK, Shimada M, Deem K, Coleman H, et al. 672 
PRKDC mutations in a SCID patient with profound neurological 673 
abnormalities. J Clin Invest 2013; 123:2969-80. 674 
18. Buck D, Malivert L, de Chasseval R, Barraud A, Fondaneche MC, 675 
Sanal O, et al. Cernunnos, a novel nonhomologous end-joining factor, 676 
is mutated in human immunodeficiency with microcephaly. Cell 2006; 677 
124:287-99. 678 
19. Murray JE, Bicknell LS, Yigit G, Duker AL, van Kogelenberg M, 679 
Haghayegh S, et al. Extreme growth failure is a common presentation 680 
of ligase IV deficiency. Hum Mutat 2014; 35:76-85. 681 
20. Woodbine L, Gennery AR, Jeggo PA. The clinical impact of deficiency 682 
in DNA non-homologous end-joining. DNA Repair (Amst) 2014; 683 
16C:84-96. 684 
21. Kashiyama K, Nakazawa Y, Pilz DT, Guo C, Shimada M, Sasaki K, et 685 
al. Malfunction of nuclease ERCC1-XPF results in diverse clinical 686 
manifestations and causes Cockayne syndrome, xeroderma 687 
 32 
pigmentosum, and Fanconi anemia. Am J Hum Genet 2013; 92:807-19. 688 
22. Jia N, Nakazawa Y, Guo C, Shimada M, Sethi M, Takahashi Y, et al. A 689 
rapid, comprehensive system for assaying DNA repair activity and 690 
cytotoxic effects of DNA-damaging reagents. Nat Protoc 2015; 691 
10:12-24. 692 
23. Verkaik NS, Esveldt-van Lange RE, van Heemst D, Bruggenwirth HT, 693 
Hoeijmakers JH, Zdzienicka MZ, et al. Different types of V(D)J 694 
recombination and end-joining defects in DNA double-strand break 695 
repair mutant mammalian cells. Eur J Immunol 2002; 32:701-9. 696 
24. Du L, Peng R, Bjorkman A, Filipe de Miranda N, Rosner C, Kotnis A, 697 
et al. Cernunnos influences human immunoglobulin class switch 698 
recombination and may be associated with B cell lymphomagenesis. J 699 
Exp Med 2012; 209:291-305. 700 
25. Stavnezer J, Bjorkman A, Du L, Cagigi A, Pan-Hammarstrom Q. 701 
Mapping of switch recombination junctions, a tool for studying DNA 702 
repair pathways during immunoglobulin class switching. Adv 703 
Immunol 2010; 108:45-109. 704 
26. Pan Q, Petit-Frere C, Dai S, Huang P, Morton HC, Brandtzaeg P, et al. 705 
Regulation of switching and production of IgA in human B cells in 706 
donors with duplicated alpha1 genes. Eur J Immunol 2001; 707 
31:3622-30. 708 
27. Riballo E, Woodbine L, Stiff T, Walker SA, Goodarzi AA, Jeggo PA. 709 
XLF-Cernunnos promotes DNA ligase IV-XRCC4 re-adenylation 710 
following ligation. Nucleic Acids Res 2009; 37:482-92. 711 
28. Neilan EG, Delgado MR, Donovan MA, Kim SY, Jou RL, Wu BL, et al. 712 
Response of motor complications in Cockayne syndrome to 713 
carbidopa-levodopa. Arch Neurol 2008; 65:1117-21. 714 
29. Wu PY, Frit P, Meesala S, Dauvillier S, Modesti M, Andres SN, et al. 715 
Structural and functional interaction between the human DNA repair 716 
proteins DNA ligase IV and XRCC4. Molecular and cellular biology 717 
2009; 29:3163-72. 718 
30. Modesti M, Junop MS, Ghirlando R, van de Rakt M, Gellert M, Yang W, 719 
et al. Tetramerization and DNA ligase IV interaction of the DNA 720 
 33 
double-strand break repair protein XRCC4 are mutually exclusive. J 721 
Mol Biol 2003; 334:215-28. 722 
31. Dai Y, Kysela B, Hanakahi LA, Manolis K, Riballo E, Stumm M, et al. 723 
Nonhomologous end joining and V(D)J recombination require an 724 
additional factor. Proc Natl Acad Sci U S A 2003; 100:2462-7. 725 
32. Pan-Hammarstrom Q, Jones AM, Lahdesmaki A, Zhou W, Gatti RA, 726 
Hammarstrom L, et al. Impact of DNA ligase IV on nonhomologous 727 
end joining pathways during class switch recombination in human 728 
cells. J Exp Med 2005; 201:189-94. 729 
33. Shaheen R, Faqeih E, Ansari S, Abdel-Salam G, Al-Hassnan ZN, 730 
Al-Shidi T, et al. Genomic analysis of primordial dwarfism reveals 731 
novel disease genes. Genome Res 2014; 24:291-9. 732 
34. Girard PM, Kysela B, Harer CJ, Doherty AJ, Jeggo PA. Analysis of 733 
DNA ligase IV mutations found in LIG4 syndrome patients: the impact 734 
of two linked polymorphisms. Hum Mol Genet 2004; 13:2369-76. 735 
35. Riballo E, Critchlow SE, Teo SH, Doherty AJ, Priestley A, Broughton B, 736 
et al. Identification of a defect in DNA ligase IV in a radiosensitive 737 
leukaemia patient. Curr Biol 1999; 9:699-702. 738 
36. Riballo E, Doherty AJ, Dai Y, Stiff T, Oettinger MA, Jeggo PA, et al. 739 
Cellular and biochemical impact of a mutation in DNA ligase IV 740 
conferring clinical radiosensitivity. J Biol Chem 2001; 276:31124-32. 741 
37. O'Driscoll M, Cerosaletti KM, Girard PM, Dai Y, Stumm M, Kysela B, 742 
et al. DNA ligase IV mutations identified in patients exhibiting 743 
developmental delay and immunodeficiency. Mol Cell 2001; 8:1175-85. 744 
38. Windhofer F, Wu W, Iliakis G. Low levels of DNA ligases III and IV 745 
sufficient for effective NHEJ. J Cell Physiol 2007; 213:475-83. 746 
39. Deriano L, Roth DB. Modernizing the nonhomologous end-joining 747 
repertoire: alternative and classical NHEJ share the stage. Annu Rev 748 
Genet 2013; 47:433-55. 749 
40. Ghezraoui H, Piganeau M, Renouf B, Renaud JB, Sallmyr A, Ruis B, et 750 
al. Chromosomal translocations in human cells are generated by 751 
canonical nonhomologous end-joining. Mol Cell 2014; 55:829-42. 752 
41. Oh S, Harvey A, Zimbric J, Wang Y, Nguyen T, Jackson PJ, et al. DNA 753 
 34 
ligase III and DNA ligase IV carry out genetically distinct forms of end 754 
joining in human somatic cells. DNA Repair (Amst) 2014; 21:97-110. 755 
42. Zha S, Guo C, Boboila C, Oksenych V, Cheng HL, Zhang Y, et al. ATM 756 
damage response and XLF repair factor are functionally redundant in 757 
joining DNA breaks. Nature 2011; 469:250-4. 758 
43. Liu S, Opiyo SO, Manthey K, Glanzer JG, Ashley AK, Amerin C, et al. 759 
Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and 760 
checkpoint activation in response to replication stress. Nucleic Acids 761 
Res 2012; 40:10780-94. 762 
44. Gigi V, Lewis S, Shestova O, Mijuskovic M, Deriano L, Meng W, et al. 763 
RAG2 mutants alter DSB repair pathway choice in vivo and illuminate 764 
the nature of 'alternative NHEJ'. Nucleic Acids Res 2014; 42:6352-64. 765 
45. Ochi T, Blackford AN, Coates J, Jhujh S, Mehmood S, Tamura N, et al. 766 
DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to 767 
promote DNA double-strand break repair. Science 2015; 347:185-8. 768 
46. Rosin N, Elcioglu NH, Beleggia F, Isguven P, Altmuller J, Thiele H, et 769 
al. Mutations in XRCC4 cause primary microcephaly, short stature 770 
and increased genomic instability. Hum Mol Genet 2015. 771 
47. Murray JE, van der Burg M, H IJ, Carroll P, Wu Q, Ochi T, et al. 772 
Mutations in the NHEJ component XRCC4 cause primordial dwarfism. 773 
Am J Hum Genet 2015; 96:412-24. 774 
48. de Bruin C, Mericq V, Andrew SF, van Duyvenvoorde HA, Verkaik NS, 775 
Losekoot M, et al. An XRCC4 splice mutation is associated with severe 776 
short stature, gonadal failure, and early-onset metabolic syndrome. J 777 
Clin Endocrinol Metab 2015:jc20151098. 778 
49. Bee L, Nasca A, Zanolini A, Cendron F, d'Adamo P, Costa R, et al. A 779 
nonsense mutation of human XRCC4 is associated with adult-onset 780 
progressive encephalocardiomyopathy. EMBO Mol Med 2015. 781 
50. Frank KM, Sharpless NE, Gao Y, Sekiguchi JM, Ferguson DO, Zhu C, 782 
et al. DNA ligase IV deficiency in mice leads to defective neurogenesis 783 
and embryonic lethality via the p53 pathway. Mol Cell 2000; 784 
5:993-1002. 785 
51. Enervald E, Du L, Visnes T, Bjorkman A, Lindgren E, Wincent J, et al. 786 
 35 
A regulatory role for the cohesin loader NIPBL in nonhomologous end 787 
joining during immunoglobulin class switch recombination. J Exp Med 788 
2013; 210:2503-13. 789 
52. Nakazawa Y, Yamashita S, Lehmann AR, Ogi T. A semi-automated 790 
non-radioactive system for measuring recovery of RNA synthesis and 791 
unscheduled DNA synthesis using ethynyluracil derivatives. DNA 792 
Repair (Amst) 2010; 9:506-16. 793 
53. Limsirichaikul S, Niimi A, Fawcett H, Lehmann A, Yamashita S, Ogi T. 794 
A rapid non-radioactive technique for measurement of repair synthesis 795 
in primary human fibroblasts by incorporation of ethynyl deoxyuridine 796 
(EdU). Nucleic Acids Res 2009; 37:e31. 797 
 798 
 799 
Figure legends 800 
Figure 1. Identification of mutations in the XRCC4 gene in CSL16NG 801 
(A) Clinical pictures of CSL16NG at age 1.5, 16 and 23 (with informed written consent 802 
from the patient’s mother). (B) Immunoblotting of XRCC4 and LIG4 proteins in 803 
CSL16NG and HCT116-XRCC4 (-/-) cells as well as normal 48BR, 1BR.3 and 804 
HCT116 cells with alpha-tubulin as a loading control. The black solid arrows indicate 805 
the position of each protein. The dilutions indicate that the amount of XRCC4 in 806 
the patient cells is < 2% (detection limit) of normal cells. (C) Immunoblots 807 
showing the expression of LIG4 proteins in normal (48BR), patient (CSL16NG) and 808 
N114P2 (LIG4 -/-) fibroblasts. (D) Immunofluorescent staining of endogenous XRCC4 809 
protein in normal 48BR, CSL16NG cells. Cells were fixed and immunostained with 810 
mouse anti-XRCC4 antibody (C4, Green). DAPI, DAPI staining (Blue); Merge, merged 811 
picture; Scale bar, 20 µm. 812 
 813 
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Figure 2. CSL16NG defects in DNA double strand break repair 814 
(A) The colony-forming ability of primary CSL16NG cells was compared with that of a 815 
normal control (1BR.3) and that of a LIG4-defective F07/614 cells after treatment with 816 
different doses of Ȗ-ray. The range of sensitivity displayed by another healthy individual 817 
and 20 other individuals deemed to have a normal (or close to normal) response is 818 
shown in Figure S4. In (A), all primary cell lines used were between 5 and 9 passages 819 
following establishment from a skin biopsy. Error bars represent S.D. obtained from 820 
triplicate experiments. (B) CSL16NG cell sensitivity to Ȗ-ray was rescued by 821 
overexpression of the WT XRCC4 protein. Cell proliferation β4 hrs after Ȗ-irradiation 822 
was determined by EdU incorporation and compared with that in unirradiated cells. (C) 823 
Complementation of the DSB repair defect in CSL16NG cells. CSL16NG cells stably 824 
expressing the V5-tagged WT XRCC4 or the indicated mutant XRCC4 proteins were 825 
irradiated with 3 Gy IR. DSB repair kinetics was measured as described above. In (B,C), 826 
primary cell lines used were between 16 and 20 passages following establishment from 827 
a skin biopsy. Error bars represent S.D. obtained from triplicate experiments. 828 
 829 
Figure 3. The XRCC4-Fs-DNA ligase IV complex has normal ligase activity 830 
(A) His-tagged LIG4 and the FLAG-tagged WT and the mutant XRCC4 proteins were 831 
expressed in HEK293FT cells. Total cell lysates were prepared and the XRCC4-DNA 832 
ligase IV complexes were purified on anti-FLAG M2 beads as described in Materials 833 
and Methods. Purified proteins were run on a SDS-PAGE and either stained with 834 
Coomassie brilliant blue (left panel) or immunoblotted with antibodies against LIG4 or 835 
XRCC4 as indicated (right panel). (B) GST-tagged XLF was purified from E. coli BL21 836 
according to the methods described previously.27 (C) The purified XRCC4-DNA ligase 837 
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IV complexes and XLF were incubated with the indicated Cy5-labeled and non-labeled 838 
dsDNA substrates. Ligated products diagrammed at right of figure were identified on 839 
1 % agarose gel electrophoresis by their decreased mobility. 840 
 841 
Figure 4. XRCC4-Fs mutant protein is unstable in cells 842 
(A) Immunoblots of the WT and mutant XRCC4 proteins with CHX (100 μg/ml). (B) 843 
Effects of various chemical compounds on degradation of the XRCC4-Fs protein. 844 
HEK293FT cells were transiently transfected with the XRCC4-Fs cDNA and treated 845 
with cycloheximide together with proteasome inhibitors, MG1γβ (β0 μM) or 846 
epoxomicin (1 μM), protease inhibitor E64D (β0 μM), or autophagy inhibitor 3-MA (10 847 
mM) for the indicated period. DMSO was used as a vehicle control. (C) Overexpression 848 
the WT and the mutant XRCC4 proteins restored LIG4 expression levels. V5-tagged 849 
XRCC4-Wt or mutant proteins were ectopically expressed in CSL16NG cells and the 850 
levels of LIG4 were analysed by immunoblotting with two different antibodies. 851 
 852 
Figure 5. CSL16NG cells show an exceptionally marked DSB repair defect. 853 
(A) Double strand break (DSB) repair kinetics following Ȗ-irradiation were determined 854 
in normal and various DSB-repair deficient patient cell lines. Residual DSBs were 855 
measured by enumeration of the average number of ȖHβAX foci at each indicated time 856 
point. (B) Immunoblots showing the expression of XRCC4, LIG4 and XLF proteins in 857 
cells from normal individuals (1BR.3), patient (CSL16NG) as well as previously 858 
reported XLF-patient (2BN) and LIG4-patients (F07/614 and 2303). (C) Diminished 859 
expression of the LIG4 in CSL16NG cells were confirmed by immunofluorescent 860 
staining. DAPI, DAPI (Blue). All primary fibroblasts used were between 5 and 9 861 
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passages following establishment from a skin biopsy. Error bars represent S.D. obtained 862 
from triplicate experiments.  863 
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Table 1. Increased microhomology-dependent repair in CSL16NG ells in 864 
plasmid-based NHEJ assaya  865 
Cell line 
Direct 
end-joining 6bp MH Deletion+MH 
Deletion 
only 
Total No. of 
junctions 
CSL16NG 
1 
(2%)***↓ 
47 
(78%)***↑ 
3 
(5%) 
9 
(15%) 
60 
XLF-/-b 
3 
(4%)***↓ 
55 
(81%)***↑ 
10 
(15%) 
0 
(0%)**↓ 
68 
411BR 
LIG4dc 
4 
(22%)***↓ 
12 
(67%)***↑ 
0 
(0%) 
2 
(11%) 
18 
Controlsd  
105 
(72%) 
11 
(8%) 
14 
(10%) 
16 
(11%) 
146 
a. Statistical calculations performed by 2 test. Significant changes are indicated in bold. 866 
*p<0.05, **p<0.01, ***p<0.001 867 
b. Previously published results from XLF-deficient cell line.24 868 
c. 411BR, described in.16, 50 869 
d. Newly generated results merged with previously published results from control cell 870 
line.24, 51 871 
  872 
 40 
Table 2. Increased fidelity of end joining at coding junctions in CSL16NG in 873 
plasmid-based VDJ-assaya 874 
Cell line 
Accurate 
end-joining 
4bp MH Deletion+MH 
Deletion 
only 
Total No. of 
junctions 
CSL16NG 
18 
(90%)***↑ 
0 
(0%)*↓ 
2 
(10%)**↓ 
0 
(0%)*↓ 
20 
XLF-/- 
5 
(12%) 
4 
(10%) 
32 
(78%)***↑ 
0 
(0%)***↓ 
41 
Controls 
13 
(10%) 
25 
(20%) 
57 
(46%) 
30 
(24%) 
125 
a. Statistical calculations performed by 2 test. Significant changes are indicated in bold. 875 
*p<0.05, **p<0.01, ***p<0.001  876 
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Table 3. Characterization of S-S junctionsa 877 
a. Statistical analysis was performed using 2 test and significant differences are 878 
indicated in bold. * p<0.05, ** p<0.01, *** p<0.001. 879 
b. Previously published junctions from LIG4-deficient patients and controls.32 880 
n= Indicates number of individuals in each group. 881 
  882 
Patients Perfectly matched short homology 
Total No. of 
S fragments 
 0 bp 1-3 bp 4-6 bp 7-9 bp ≥ 10 bp  
 
Direct 
end-joinin
g 
Small 
insertion
s 
     
CSL16NG 
(n=1) 
1 
(5%) 
2 
(9%) 
4 
(18%) 
2 
(9%) 
5 
(23%)*↑ 
8 
(36%)***↑ 
22 
LIG4db 
(n=2) 
0 
(0%)*↓ 
1 
(3%)**↓ 
7 
(23%) 
4 
(13%) 
4 
(13%) 
14 
(47%)***↑ 
30 
Controlsb 
(n=17) 
28 
(18%) 
39 
(25%) 
56 
(36%) 
15 
(10%) 
11 
(7%) 
5 
(3%) 
154 
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Supplemental Materials 883 
 884 
Supplemental methods 885 
 886 
RRS, UDS and RDS assays 887 
Detailed experimental procedures have been described previously.22, 52, 53 Briefly, 888 
normal 48BR, CSL16NG and XPA patient-derived primary fibroblasts (XP15BR) were 889 
seeded in 96-well plates (BD Falcon). For RRS assay, cells were UV-irradiated (254 nm 890 
UVC, 12 J/cm2) and incubated for 12 hours for RNA synthesis recovery, followed by 891 
ethynyluridine (EU) incorporation. For the UDS and RDS assays, UV- or -ray 892 
irradiated cells were immediately incubated with 5’-ethynyl-β’-deoxyuridine (EdU) for 893 
measuring repair synthesis. After incorporation of EdU or EU, cells were fixed, 894 
followed by Alexa Fluor 488-azide coupling and DAPI staining. Image acquisition and 895 
data processing were automated using the Cellomics ArrayScan VTI (Thermo 896 
Scientific). 897 
 898 
Identification of the pathogenic mutations by exome sequencing 899 
  We performed exome sequencing of the patient, CSL16NG, using the Agilent 900 
SureSelect Exome Target Enrichment System (version.5 50Mbp target), followed by 901 
paired-end sequencing (101 bp/read) on the Illumina Hiseq 2500 sequencer. We 902 
obtained ~193 million reads (~ 19 Giga base pairs). Of the QC-passed initial sequencing 903 
reads, 18.4 Gbp are uniquely mapped to the human reference sequence (b37). Of the 904 
mapped sequences, 12.9 Gbp (66.33%) are further mapped to the target exon regions 905 
with a mean coverage of 89.05x. 98.8% of the target bases were read more than 2x 906 
coverage. We identified a total of 740,166 single nucleotide variants (SNVs) and 88,210 907 
insertions and deletions (indels). To identify potential pathogenetic changes, we firstly 908 
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determined 'functionally significant variants', which are coding non-synonymous SNVs, 909 
stopgains and stoplosses, splice-site variants, and coding indels. We identified 11,505 910 
functionally significant variants. The identified variants were then filtered out to extract 911 
'novel functionally significant variants'. We compared the identified variants with 912 
dbSNP137, 1000 Genomes Project, and 88 in-house exome sequencing data. Variants 913 
found in these databases were excluded. As a consequence of these filtering process, 914 
totally 140 novel functionally significant variants were determined. Based on a 915 
recessive inheritance model, we found 5 pathogenic candidate genes in the patient 916 
(Table S1). 917 
  918 
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Table S1. Novel homozygous and compound heterozygous variants in the 919 
candidate genes identified by the exome sequencing of the patients CSL16NG. 920 
Patient Chr. Position Genotype Gene 
Mutation 
type 
Nucleotide 
change 
Amino-acid 
change 
CSL16NG 3 184104702 Het CHRD ns c.G2266A p.D756N 
CSL16NG 3 184103873 Het CHRD ns c.C1858T p.R620W 
CSL16NG 5 82554363 Het XRCC4 fs del c.760delG p.D254fs 
CSL16NG 5 82500668 Het XRCC4 sg c.673T p.R225* 
CSL16NG 9 35906600 Hom HRCT1 fs ins c.316_317insA p.P106fs 
CSL16NG 11 1266064 Het MUC5B ns c.A7963G p.I2655V 
CSL16NG 11 1247871 Het MUC5B ns c.G226T p.V76L 
CSL16NG 19 1863385 Hom KLF16 ns c.G112A p.A38T 
Abbreviations used in this table: Chr., chromosome; Position, refseq position of the 921 
variant; Genotype, Hom / homozygous, Het / heterozygous; Gene, gene symbol in which 922 
the variant is located; Mutation type, ns / nonsynonymous missense, fs del / frameshift 923 
deletion, fs ins / frameshift insertion, sg / stop gain; Nucleotide change, base change and 924 
base number resulting from the observed variant; Amino acid change, amino acid change 925 
and codon number resulting from the observed variant.  926 
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Table S2. Blood immunological tests on CSL16NG 927 
Immunological parameter Value Age-related normal range 
CD3 1973 cells/l (690-2540) 
CD4 1210 cells/l (410-1590) 
CD8 744 cells/l (190-1140) 
CD19 615 cells/l (90-660) 
CD16/56 1506 cells/l (90-590) 
CD45RACD27 200 cells/l  
TCRαȕ 98%  
TCRȖδ 2%  
CD27-IgM+IgD+ 85%  
CD27+IgM+IgD+ 5%  
CD27+IgM-IgD- 7%  
IgM 1.66 g/L (0.71-2.30) 
IgA 1.26 g/L (0.64-2.97) 
IgG 7.7 g/L (5.8-15.4) 
  928 
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Table S3. Primers used for allele-specific amplification. 929 
Primer designation Primer sequence 
XRCC4-F 5’-GTGTGAGTGCTAAGGAAGCTTTGG-γ’ 
XRCC4-WT-R 5’-TACTCTCATCATAGACTGGATCTCG-γ’ 
XRCC4-ter-R 5’-TACTCTCATCATAGACTGGATCTCA-γ’ 
XRCC4-com-R 5’-GTACTCTCATCATAGACTGGATCTC-γ’ 
XRCC4-R 5’-CTTCTGGGCTGCTGTTTCTCAGAG-γ’ 
XRCC4-WT-F 5’-TTCAGCTGCTGTAAGTAAAG-γ’ 
XRCC4-fs-F 5’-TTCAGCTGCTGTAAGTAAAA-γ’ 
XRCC4-com-F 5’-CTTCAGCTGCTGTAAGTAAA-γ’ 
  930 
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Supplemental Figures 931 
Figure S1 Construction of XRCC4 mutants  932 
(A) Sequence validation of constructed pLenti-6.3-XRCC4-Del and 933 
pLenti-6.3-XRCC4-Fs plasmid DNA. Red arrows indicated mutation sites. (B) 934 
Sequence validation of constructed pLenti-6.3-XRCC4-W43R plasmid DNA. 935 
 936 
Figure S2. CSL16NG cells display normal NER activity 937 
(A) Recovery of RNA synthesis (RRS) and (B) unscheduled DNA synthesis (UDS) are 938 
normal in CSL16NG. Nucleotide excision repair (NER)-proficient normal 48BR and 939 
-deficient XP15BR cells were used as controls. (XP represents xeroderma pigmentosum, 940 
a human disorder caused by NER-deficiency. XP causes sensitivity to ultraviolet (UV) 941 
irradiation and not to ionising radiation). Filled bars, 12 J/m2 of 254 nm UV-C; open 942 
bars, no UV. (C) UV-sensitivity of different cell strains was determined after different 943 
doses of UVC irradiation, and their viability measured by their ability to incorporate 944 
EdU (5 μM, 1 h incubation) 24 hours after treatment. (D) Normal expression levels of 945 
the CSB and XPG proteins in CSL16NG cells. (E) Quantitation of data in (D). N.S., no 946 
statistically significant difference. All primary cell lines used were between 16 and 20 947 
passages following establishment from a skin biopsy. 948 
 949 
Figure S3. Expression of the XRCC4 pathogenic alleles in CSL16NG cells 950 
(A) Capillary Sanger sequencing confirmed that the patient is compound heterozygous 951 
for the c.673C>T in XRCC4 exon 6, resulting in the premature stopgain p.R225* 952 
(inherited from the mother) as well as for the c.760delG in XRCC4 exon 7, causing the 953 
frameshift p.D254fs*68 (inherited from the father). The altered amino acids are shown 954 
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in red. (B) Locations of the primer sets used for the qRT-PCR experiments are depicted. 955 
(C) Selective quantitative amplification of the WT and the mutational p.Arg225* 956 
XRCC4 alleles in CSL16NG, and normal 48BR cells. Allele-specific primers selectively 957 
amplify the WT (c.673C) allele (XRCC4-F and XRCC4-WT-R, left panel), the 958 
pathogenic mutant (c.673C>T) allele (XRCC4-F and XRCC4-ter-R, middle panel), and 959 
both alleles at once (XRCC4-F and XRCC4-com-R, right panel). (D) Selective 960 
quantitative amplification of the WT and the mutational p.Asp254fs*68 XRCC4 alleles 961 
in CS16LNG, and normal 48BR cells. Allele-specific primers selectively amplify the 962 
WT (c.760G) (XRCC4-WT-F and XRCC4-R, left panel), the pathogenic mutant 963 
(c.760del) allele (XRCC4-fs-F and XRCC4-R, middle panel), and both alleles at once 964 
(XRCC4-com-F and XRCC4-R, right panel). Transcripts from the HPRT1 gene were 965 
used as a quantification control. All primary cell lines used were between 16 and 20 966 
passages following establishment from a skin biopsy. 967 
 968 
Figure S4 Range of radiosensitivity observed in normal patients. 969 
Figure 2A shows the sensitivity of CSL16NG primary fibroblasts relative to control 970 
cells. To confirm that the sensitivity of CSL16NG cells lies outside of the normal range, 971 
we firstly compared the sensitivity to 1BR.3 and 48BR primary fibroblasts, both of 972 
which are derived from a healthy individual. The sensitivity of 48BR cells was similar 973 
to that shown by 1BR.3 cells. To assess the magnitude of sensitivity of a broader range 974 
of individuals, we included the analysis of the most recent 20 primary fibroblasts lines 975 
from individuals whose cells were sent to our laboratory for analysis. These individuals 976 
had a range of clinical features, including aspects of immunodeficiency. We excluded all 977 
cell lines where we had an identified genetic defect. Since these cell lines were from 978 
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non-healthy individuals, we excluded the two most sensitive lines, considering that they 979 
might be from individuals with minor genetic defects affecting radiosensitivity, 980 
resulting in the analysis of 90% of this patient subset, which we considered might 981 
represent the response of a 90% percentile. The figure shows the range of sensitivity 982 
displayed by these 18 cell lines. The response of 1BR.3 and 48BR lies within this range.  983 
The lower edge of this range may be slightly more sensitive than the true responses of 984 
healthy individuals since our 18 patients were individuals with health issues. CSL16NG 985 
cells were substantially outside of this normal range. 986 
 987 
Figure S5. Increased microhomology usage at S-S junctions from CSL16NG 988 
(A) Schematic picture showing regions encoding IgM (C) and IgA (C) on IGH locus. 989 
An S-S junction created after switching from IgM to IgA is depicted below. (B) 990 
Switch fragments from either control (C369) or patient (CSL16NG) aligned with 991 
germline S and S sequences are shown. Determination of repair pattern was 992 
performed as previously described.25. Repair by direct end-joining is designated by 993 
straight line, small insertion is underlined and microhomology-based end-joining is 994 
marked by a box. The positions of break points in germline S regions are indicated by 995 
▼ or ▲.  996 
 997 
Figure S6 Ectopic expression of the XRCC4 mutant proteins  998 
(A) Schematic representation of human full-length XRCC4 and XRCC4 mutants used 999 
for the complementation analyses. The light blue box indicates an aberrant C-terminal 1000 
68 amino acids (aa). (B) Percentages of XRCC4 expressing cells were confirmed by 1001 
immunofluorescent staining of the V5-tagged proteins. 1002 
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 1003 
Figure S7. XRCC4 cDNA complements the DSB repair defect (53BP1) 1004 
(A, B) 1BR.3 normal, and CSL16NG hTERT immortalized fibroblasts were transfected 1005 
with GFP-tagged full-length XRCC4 cDNA (XRCC4-Wt) or mutant XRCC4 1006 
(XRCC4-Fs). 24 hours after transfection, cells were irradiated with γ Gy Ȗ-rays, and the 1007 
number of 53BP1 foci in GFP-positive cells was enumerated at 0.25 and 8 hours. 1008 
Substantial correction of the DSB repair defect of patient cells was observed upon 1009 
expression of both WT and mutant XRCC4 cDNA. No correction was observed after 1010 
transfection of XRCC4 cDNA into LIG4-defective cells. BG, background (no 1011 
irradiation); Error bars, S.D. of mean of triplicate experiments. In this experiment, the 1012 
green channel detected both 53BP1 + GFP-tagged XRCC4. It was possible to identify 1013 
defined 53BP1 foci above the background GFP signals of transfected cells although this 1014 
is difficult to convey in the images. 53BP1 foci were enumerated in untransfected (low 1015 
pan nuclear GFP signal) and in transfected (high pan nuclear signal) cells. 1016 
Untransfected 1BR.3 cells have a strong XRCC4 signal, some residual 53BP1 foci at 8 1017 
h post 3 Gy and little background GFP signal. Untransfected CSL16NG cells have a low 1018 
XRCC4 signal, elevated 53BP1 foci compared to 1BR.3 cells. Transfected CSL16NG 1019 
cells expressing WT-XRCC4 have close to a WT level of XRCC4, reduced residual 1020 
53BP1 foci and strong GFP pan nuclear staining. Transfected CSL16NG cells 1021 
expressing XRCC4-Fs showed a good nuclear staining of XRCC4 as well as some 1022 
cytoplasmic staining, a strong pan nuclear signal of GFP and a number of 53BP1 foci 1023 
that was slightly higher than that shown in cells expressing WT-XRCC4. The 1024 
enumeration of 53BP1 foci in untransfected 1BR.3 or CSL16NG cells was similar to 1025 
that observed in other experiments using these cells. 1026 
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 1027 
Figure S8. Proteasomal degradation of the endogenous XRCC4-Fs mutant protein 1028 
(A) Normal 48BR and CSL16NG cells were treated with CHX (100 μg/ml), MG1γβ (β0 1029 
μM), or with epoxomicin (1 μM) for 1β hours. Immunofluorescent staining was 1030 
conducted using mouse anti-XRCC4 antibody (C4, Green). DAPI, DAPI staining 1031 
(Blue); Merge, merged picture; Alexa 488 only, staining only with Alexa fluor 1032 
488-conjugated secondary antibody; Scale bar, 100 μm. (B) 48BR and CSL16NG cells 1033 
were treated with MG1γβ (β0 μM) for 1β hours, the total cell lysates were subjected to 1034 
SDS-PAGE and Western Blotting analysis using anti-XRCC4 or anti-DNA Ligase IV 1035 
antibodies. 1036 
 1037 
Figure S9. CSL16NG defects in DSB repair  1038 
(A) Normal 1BR.3 and CSL16NG primary fibroblasts were irradiated with 0.5 Gy -ray. 1039 
The average number of H2AX foci was enumerated at the indicated times. Results 1040 
represent the mean +/- S.D. of 3 experiments. (B) Normal 48BR, CSL16NG, 2BN 1041 
(XLF-defective) and 2303 (LIG4 syndrome) cells were untreated or treated with 3 Gy 1042 
-ray and incubated for 8 days to allow DSB repair. H2AX foci were enumerated at the 1043 
indicated times. Results represent the mean +/- S.D. of 3 experiments (C) Normal 48BR 1044 
and CSL16NG cells were treated with 3 Gy -irradiation and incubated with or without 1045 
the 0.5 M PARP inhibitor (KU58958, a kind gift from AstraZeneca) or 5 mM 1046 
DNA-PK inhibitor (NU7441, Stratech Scientific, UK) for the indicated times. (D) Left 1047 
panel, knockdown of LIG4 in CSL16NG hTERT cells shows an additive DSB repair 1048 
defect demonstrating that there is residual NHEJ activity. “+ LigIV kd” represents 1049 
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knockdown of LIG4 prior to IR and H2AX analysis; Right panel images show two 1050 
cells (top image, DAPI; 2nd image, H2AX; 3rd and 4th image, LIG4). The cell with a 1051 
solid asterisk has undergone knockdown, the other has not. The cell with knockdown 1052 
has a greater level of DSBs remaining as shown by intense H2AX staining. The bottom 1053 
image has been amplified to show enhanced intensity of staining. This image shows that 1054 
even in the knocked down CSL16NG hTERT cells, there is residual detectable LIG4. 1055 
Thus, the residual DSB rejoining is most likely still attributable to residual NHEJ. All 1056 
primary cell lines used were between 5 and 9 passages following establishment from a 1057 
skin biopsy. Error bars in panels A and B represent S.D. obtained from triplicate 1058 
experiments. Where only two experiments were carried out (C and D) individual 1059 
experiments have been plotted side by side. 1060 
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